aprepitant profile

Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135413536
CHEMBL ID	1471
CHEBI ID	499361
SCHEMBL ID	264924
MeSH ID	M0447596

Synonym
HY-10052
c23h21f7n4o3
AB01274775-01
AB01275535-01
ono-7436
aprepitant
mk-0869
mk-869
l-754030
emend
aprepitant (jan/usp/inn)
emend (tn)
170729-80-3
cinvanti (tn)
D02968
NCGC00181785-01
DB00673
3h-1,2,4-triazol-3-one, 5-(((2r,3s)-2-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-
3h-1,2,4-triazol-3-one, 5-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-, (2r-(2alpha(r*),3alpha))-
l 754030
mk 869
aprepitant [usan]
mk 0869
3-(((2r,3s)-3-(p-fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
HMS2090N12
CHEMBL1471 ,
nsc-748825
l-754,030
5-(((2r,3s)-2-((r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-2h-1,2,4-triazol-3(4h)-one
5-[(2r,3s)-2-[(r)-1-(3,5-bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one
3-[2-{1-[3,5-di(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-1,4-oxazinan-4-ylmethyl]-4,5-dihydro-1h-1,2,4-triazol-5-one
bdbm50220136
5-{[(2r,3s)-2-{(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3h-1,2,4-triazol-3-one
aprepitantum
3-(((2r,3s)-3-(p-fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
chebi:499361 ,
3h-1,4-triazol-3-one, 5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-
nsc748825
3-[((2r,5-bis(trifluoromethyl)benzyl]oxy}morpholino)methyl]-.delta.2-1,2,4-triazolin-5-one
5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
ono 7436
nsc 748825
aprepitant [usan:inn:jan]
cinvanti
mk0869
1nf15yr6uy ,
unii-1nf15yr6uy
3h-1,2,4-triazol-3-one, 5-(((2r,3s)-2-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-2,4-dihydro-
cas-170729-80-3
dtxcid801021794
tox21_113595
dtxsid3049047 ,
BCP9000312
AKOS015969344
aprepitant,mk-0869, l-754030, emend
5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one
CS-0487
S1189
AKOS015895498
BRD-K52827117-001-01-6
gtpl3490
aprepitant [usp-rs]
aprepitant [inn]
aprepitant [orange book]
aprepitant [usp monograph]
aprepitant [mi]
aprepitant [ep monograph]
aprepitant [mart.]
aprepitant [jan]
aponvie
aprepitant [ema epar]
3-(((2r,3s)-3-(p-fluorophenyl)-2-(((.alpha.r)-.alpha.-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-.delta.(sup 2)-1,2,4-triazolin-5-one.
aprepitant [vandf]
aprepitant [who-dd]
CCG-220747
SCHEMBL264924
smr002530053
MLS006011068
NCGC00344566-01
tox21_113595_1
Q-200647
3-(((2r,3s)-2-((r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1h-1,2,4-triazol-5(4h)-one
AB01274775_02
3-{[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1h-1,2,4-triazol-5-one
3-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
C21555
EX-A212
aprepitant`
SR-05000001531-1
sr-05000001531
emende
HMS3714E16
5-(((2r,3s)-2-((r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1h-1,2,4-triazol-3(2h)-one
aprepitant, united states pharmacopeia (usp) reference standard
aprepitant (mk-0869, l-754030)
321125-94-4
3h-1,2,4-triazol-3-one, 5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, rel-
aprepitant, form i
aprepitant, form ii
aprepitant (mk-0869) ,
AS-14638
HMS3884G05
CCG-264854
NCGC00181785-11
aprepitant- bio-x
BA164216
aprepitant (usp monograph)
aprepitant (ep monograph)
a04ad12
aprepitant (mart.)
aprepitant (usp-rs)
EN300-761455
3h-1,2,4-triazol-3-one,5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-,rel-
Z2937147473

Excerpt	Reference
"Aprepitant is an NK-1 antagonist used to treat nausea and vomiting."	( Aprepitant is a novel, selective activator of the K2P channel TRAAK. Avkiran, T; Byrom, L; Gaffey, F; Jerman, J; Large, JM; Mathie, A; McCoull, D; Vaitone, E; Veale, EL; Walsh, Y; Wright, PD, 2022)
"Aprepitant (Apr) is an effective antiemetic agent for chemotherapy-induced nausea and vomiting (CINV). "	( Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma. Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Mashima, K; Minakata, D; Morita, K; Nagayama, T; Nakano, H; Ohmine, K; Sato, K; Toda, Y; Ueda, M; Umino, K; Yamamoto, C; Yamasaki, R, 2022)
"Aprepitant is an important medication used to prevent chemotherapy-induced nausea and vomiting (CINV)."	( Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting. Chen, P; Li, Y; Liu, B; Sun, Y; Wang, Y; Xie, K; Zhu, J, 2022)
"Aprepitant is a neurokinin-1 receptor antagonist, and recent guidelines by the American Neurogastoenterology and Motility Society recommend its use as prophylaxis in moderate-to severe cyclic vomiting syndrome (CVS). "	( Efficacy of aprepitant as a prophylactic medication in adults with cyclic vomiting syndrome. Garacchi, Z; Kovacic, K; Mooers, H; Partovi, O; Patel, M; Venkatesan, T, 2023)
"Aprepitant is a safe and effective prophylactic medication in adults with refractory CVS. "	( Efficacy of aprepitant as a prophylactic medication in adults with cyclic vomiting syndrome. Garacchi, Z; Kovacic, K; Mooers, H; Partovi, O; Patel, M; Venkatesan, T, 2023)
"Fosaprepitant is a relevant alternative in preventing and treating PONV in patients who underwent bariatric/metabolic surgical procedures."	( Impact of Emend on Perioperative Bariatric Surgery Antiemetic Utilization, Patient Satisfaction, and Costs. Aghazarian, GS; Ghanem, M; Jawad, MA; Lastrapes, L; Lind, R; Motola, D; Perry, M; Singletary, N; Teixeira, AF, 2023)
"Aprepitant is a neurokinin-1 receptor blocker and has been shown to reduce chemotherapy-related nausea and vomiting and PONV."	( The use of aprepitant for the prevention of postoperative nausea and vomiting in endoscopic transsphenoidal pituitary surgery. Adappa, ND; Atkins, JH; Chang, J; Douglas, JE; Grady, MS; Jackson, C; Kohanski, MA; Lee, DJ; Lee, JYK; Palmer, JN; Wilensky, J; Yoshor, D, 2023)
"Aprepitant is a kind of NK-1R antagonist."	( The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages. Bai, ZZ; Li, CH; Li, HY; Sheng, CL; Zhao, XN, 2020)
"Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. "	( Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study. Anlar, B; Arioz, F; Arman-Kandirmaz, E; Gumeler, E; Konuskan, B; Oncel, I; Parlak, S; Sancar, M; Tezcan, S, 2020)
"Aprepitant is a selective SP/NK-1 receptor antagonist and used in postoperative and chemotherapeutics induced emesis and vomiting. "	( Can aprepitant used for nausea and vomiting be good gastrointestinal complaints? Bal Tastan, T; Cadirci, E; Halici, Z; Kose, D; Ugan, RA; Un, H; Yayla, M, 2020)
"Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV)."	( Aprepitant for the Treatment of Chronic Refractory Pruritus. Alhariri, JM; He, A; Kwatra, MM; Kwatra, SG; Sweren, RJ, 2017)
"Aprepitant is a NK-1 receptor antagonist."	( Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis. Bradley, M; Hall, MA; Heilborn, J; Holmberg, J; Holst, M; Killasli, H; Lönndahl, L; Nordlind, K; Theodorsson, E, 2018)
"Aprepitant is a selective high‑affinity antagonist of the human neurokinin‑1 (NK‑1) receptor (NK1R) with robust antitumor activity."	( Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Berger, M; Carranza, A; Coveñas, R; Gonzalez-Ortega, A; Muñoz, M; Rosso, M, 2014)
"Aprepitant is a neurokinin-1 receptor antagonist affecting the substance P receptor."	( Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant. Albarrán Planelles, C; Fernández Anguita, MJ; Jiménez Gallo, D; Linares Barrios, M; Márquez Enríquez, J; Rodríguez Mateos, ME, )
"Fosaprepitant is an antiemetic used for chemotherapy-induced nausea and vomiting. "	( An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Anderson, KJ; Grendahl, DC; Hegerova, LT; Hilger, CR; Leal, AD; Loprinzi, CL; Seisler, DK; Sorgatz, KM, 2015)
"Aprepitant is a neurokinin 1 receptor antagonist approved for prevention of chemotherapy-induced and post-operative nausea and vomiting. "	( Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Ball, WA; Hargreaves, RJ; Lines, C; Reines, SA; Snavely, DB; Szegedi, A, 2014)
"Aprepitant is a P/neurokinin-1 receptor antagonist approved for the prevention of CINV in moderate emetic risk chemotherapy."	( Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W, 2015)
"Aprepitant (APT) is a lipophilic, poorly water soluble drug with moderate permeability characteristic. "	( Aprepitant loaded solid preconcentrated microemulsion for enhanced bioavailability: A comparison with micronized Aprepitant. Kamboj, S; Rana, V; Sharma, R; Singh, K, 2015)
"Aprepitant is a relatively new agent for this condition which may be superior to other treatment."	( Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Borle, A; Goudra, B; Makkar, JK; Rewari, V; Singh, PM; Sinha, AC; Trikha, A, 2016)
"Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR."	( Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclit Hasuo, Y; Ichinoe, A; Kato, K; Kobayashi, H; Masuda, S; Nishida, M; Ogawa, S; Ohgami, T; Saito, T; Sakai, K; Shimokawa, M; Sonoda, K; Ueoka, Y; Yahata, H, 2016)
"Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme. "	( Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy. Hisaka, A; Ohno, Y; Suzuki, H; Takaki, J; Yamada, M; Yamaguchi, R, 2016)
"Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. "	( Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. Chau, NG; Kupper, TS; LeBoeuf, NR; Song, JS; Tawa, M, 2017)
"Aprepitant (AP) is a known inhibitor of cytochrome P450 3A4 which may affect tacrolimus metabolism. "	( Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. Abidi, MH; Ayash, LJ; Cadotte, C; Cronin, SM; Edwards, DJ; Ibrahim, RB; Jacobson, PA; Mulawa, J; Smith, DW; Uberti, JP, 2008)
"Aprepitant is a selective NK-1 receptor antagonist approved as part of combination therapy with a corticosteroid and a 5-HT(3) receptor antagonist for the prevention of acute and delayed CINV in patients receiving moderately and highly emetogenic chemotherapy."	( Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari, RM, 2008)
"Aprepitant is a selective high-affinity antagonist of human substance P (SP)/Neurokinin-1 (NK-1) receptors. "	( The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Muñoz, M; Rosso, M, 2010)
"Aprepitant (Emend) is a neurokinin-1 (NK(1)) receptor antagonist that is able to alleviate the emetic effects of substance P. "	( Aprepitant: a review of its use in the prevention of nausea and vomiting. Curran, MP; Robinson, DM, 2009)
"Aprepitant is a selective high-affinity antagonist of the human NK-1 receptor."	( The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Coveñas, R; González-Ortega, A; Muñoz, M; Robles-Frias, MJ; Rosso, M; Rosso, R; Salinas-Martín, MV, 2010)
"Aprepitant is a new neurokinin-1 (NK(1) ) receptor antagonist developed as a treatment for chemotherapy-induced nausea and vomiting (CINV). "	( Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Eguchi, K; Hoshi, E; Katsumata, N; Kawahara, M; Takagi, M; Takahashi, T, 2010)
"Fosaprepitant is an intravenous prodrug of aprepitant that offers a new alternative to patients with CINV. "	( Pharmacokinetic evaluation of fosaprepitant dimeglumine. Colon-Gonzalez, F; Kraft, WK, 2010)
"Aprepitant is a neurokin-1 receptor antagonist with a long duration of action and no sedative side effect."	( A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Borel, CO; Gan, TJ; Habib, AS; Keifer, JC; White, WD, 2011)
"Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen."	( [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. Abe, T; Hachiro, Y; Kunimoto, M, 2010)
"Fosaprepitant 150 mg is a weak inhibitor of CYP3A4."	( Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. Caro, L; Jin, B; Marbury, TC; Murphy, G; Ngo, PL; Panebianco, D; Shadle, CR; Valentine, J, 2011)
"Aprepitant is a NK1R antagonist approved by FDA as an antiemetic."	( A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. Barrett, JS; Douglas, SD; Gonin, R; Kim, D; Korelitz, J; Tebas, P; Tuluc, F; Wagner, W; Zhao, H, 2011)
"Aprepitant is a selective NK1 antagonist currently marketed for clinical use as an anti-emetic."	( Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Heilig, M; Henderson, P; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2013)
"Aprepitant (APR) is a water insoluble drug approved for the treatment of chemotherapy induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). "	( Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Ansari, KA; Dhawan, S; Kaul, NS; Krishnamurthy, T; Kumar, D; Pillai, R; Ridhurkar, DN, 2013)
"Aprepitant is a novel neurokinin 1 (NK(1)) antagonist that has been shown to improve control of chemotherapy-induced nausea and vomiting (CINV) when added to a standard antiemetic regimen of a 5-hydroxytriptamine-3 antagonist plus a corticosteroid. "	( Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Carides, AD; Eldridge, K; Evans, JK; Hipple, A; Horgan, KJ; Julie Ma, G; Lawson, F; Poli-Bigelli, S; Rodrigues-Pereira, J, 2003)
"Aprepitant is a neurokinin(1) receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine(3) receptor antagonist, has been shown to be very effective in the prevention of chemotherapy-induced nausea and vomiting. "	( Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Blum, RA; Deutsch, PJ; Gargano, C; Goldberg, MR; Goldwater, DR; Gottesdiener, KM; Hesney, M; Iwamoto, M; Lines, CR; Majumdar, AK; McCrea, JB; Murphy, MG; Panebianco, DL; Petty, KJ, 2003)
"Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. "	( Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Blum, RA; Constanzer, M; Dru, J; Goldberg, MR; Gottesdiener, KM; Hesney, M; Lines, CR; Majumdar, AK; McCrea, JB; Murphy, G; Panebianco, DL; Petty, KJ, 2003)
"Aprepitant is a highly selective neurokinin-1 receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine3 (5HT3) receptor antagonist, has been shown to be efficacious in the prevention of highly emetogenic chemotherapy-induced nausea and vomiting. "	( Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. Brackett, LE; De Smet, M; Feuring, M; Goldberg, MR; Gottesdiener, KM; Hesney, M; Lee, Y; Majumdar, AK; Michiels, N; Murphy, MG; Orlowski, LH; Petty, KJ; Wehling, M, 2003)
"Aprepitant is an oral neurokinin-1 receptor antagonist which acts centrally to block chemotherapy-induced emesis. "	( Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting. Olver, IN, 2004)
"Aprepitant is a highly selective substance P (neurokinin 1 [NK(1)] receptor) antagonist that significantly improves the pharmacotherapy of acute and delayed highly emetogenic chemotherapy-induced nausea and vomiting, probably through an action in the brain stem region of the central nervous system. "	( Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Antoni, G; Battisti, WP; Bergström, M; Bradstreet, TE; Burns, HD; Constanzer, ML; Eskola, O; Gargano, C; Goldberg, MR; Hargreaves, RJ; Hietala, J; Långström, B; Majumdar, AK; Ogren, M; Petty, KJ; Reines, SA; Scheinin, M; Sciberras, D; Solin, O, 2004)
"Aprepitant is a substrate, a moderate inhibitor and an inducer of cytochrome P450 (CYP)3A4 and CYP2C9."	( Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Navari, RM, 2004)
"Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. "	( Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Ahmed, T; Cocquyt, V; de Smet, M; Fedgchin, M; Gottesdiener, KM; Hande, K; Majumdar, A; Murphy, MG; Nygren, P; Panebianco, D; Petty, KJ; van Belle, S; van Dyck, K, 2005)
"Aprepitant is a selective antagonist of substance P/neurokinin 1 that augments the benefit of 5-HT(3) receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting."	( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005)
"Aprepitant is a neurokinin-1 (NK1)-receptor antagonist developed as an antiemetic for chemotherapy-induced nausea and vomiting."	( Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Bergman, A; Crumley, T; de Hoon, JN; De Lepeleire, I; Depré, M; Laethem, T; Majumdar, A; Oeyen, M; Panebianco, D; Petty, KJ; Rothenberg, P; Van Hecken, A, 2005)
"Aprepitant is a selective high-affinity human SP/NK1 receptor antagonist approved by the FDA in 2003."	( [Neurokinin 1 receptor antagonists--between hope and disappointment]. Fleischer, F; Nieber, K; Rost, K, 2006)
"Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and vomiting. "	( Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. Bergman, A; Constanzer, M; Dru, J; Evans, JK; Gambale, J; Han, TH; Jin, B; Lasseter, KC; Majumdar, A; Murphy, MG, 2007)
"Aprepitant is a selective NK-1 receptor antagonist approved as part of combination therapy with a corticosteroid and a 5-HT(3) receptor antagonist for the prevention of acute and delayed CINV."	( Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari, RM, 2007)

Excerpt	Reference
"Oral aprepitant has a large interindividual variation in clinical responses in advanced cancer. "	( Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients. Hosokawa, S; Kawakami, J; Naito, T; Shibata, K; Suzuki, Y, 2023)
"Aprepitant has a significant role in the management of CINV, as it allows the majority of patients to complete their chemotherapies without significant morbidity. "	( Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Chawla, SP; Giles, FJ; Pandya, DM; Sankhala, KK; Sarantopoulos, J; Soefje, SA, 2009)
"Aprepitant has been shown to reduce chemotherapy-induced nausea and vomiting in children receiving highly emetogenic chemotherapy (HEC). "	( Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial. Bakhshi, S; Ganguly, S; Giri, RK; Rasheed, AA; Sasi, A; Sharma, P; Sra, MS, 2022)
"Aprepitant has been classified into BCS class IV, which has low permeability and poor water solubility, resulting in low bioavailability. "	( Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability. Ao, W; Bai, M; Li, S; Li, Y; Liu, J; Xiao, Y, 2022)
"fosaprepitant has been approved as an alternative to 3 day oral aprepitant, a neurokinin-1 receptor antagonist, and improves prevention of chemotherapy-induced nausea and vomiting (CINV)."	( Evaluation of aprepitant and fosaprepitant in pediatric patients. Arakawa, A; Arima, T; Hashimoto, H; Ishimaru, S; Kumamoto, T; Makino, Y; Nakajima, M; Ogawa, C; Saito, Y; Shirakawa, N; Sonoda, T; Sugiyama, M; Yamaguchi, M, 2019)
"Aprepitant has shown to be effective for CINV in adults, but little is known on its effect in pediatrics."	( Emesis control by aprepitant in children and adolescents with chemotherapy. Bauters, TG; Benoit, Y; Laureys, G; Robays, H; Verlooy, J, 2013)
"Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. "	( Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. Chau, NG; Kupper, TS; LeBoeuf, NR; Song, JS; Tawa, M, 2017)
"Fosaprepitant 150 mg has been submitted to regulatory agencies for consideration of approval as a single-day alternative to the 3-day oral aprepitant antiemetic regimen currently marketed."	( Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. Caro, L; Jin, B; Marbury, TC; Murphy, G; Ngo, PL; Panebianco, D; Shadle, CR; Valentine, J, 2011)
"Aprepitant has been noted to produce modest decreases in plasma S(-)-warfarin concentrations, suggesting potential induction of CYP2C9."	( Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. Blum, RA; Bradstreet, TE; Evans, JK; Gargano, C; Lee, Y; Majumdar, AK; Petty, KJ; Shadle, CR, 2004)
"As aprepitant has been shown to be a moderate inhibitor of the cytochrome P450 (CYP) 3A4 isoenzyme, its effect on the pharmacokinetics and metabolism of cyclophosphamide and thiotepa was evaluated."	( Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Beijnen, JH; de Jonge, ME; Holtkamp, MJ; Huitema, AD; Rodenhuis, S; van Dam, SM, 2005)
"Aprepitant has been approved for the prevention and treatment of acute (0-24 h after chemotherapy) and delayed (1-5 days after chemotherapy) emesis resulting from cisplatin-based chemotherapy and moderately emetogenic chemotherapy."	( Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy. Jordan, K, 2006)
"Fosaprepitant 115 mg has been submitted for FDA approval as an alternative on day 1 of a 3-day oral aprepitant regimen, with oral aprepitant administered on days 2 and 3."	( Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari, RM, 2007)

Excerpt	Reference
"Aprepitant did not increase severe adverse events."	( Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. Bhattacharjee, A; Ishi, S; Joshi, A; Kannan, S; Maske, K; Menon, N; Mukadam, SA; Noronha, V; Patil, VM; Prabhash, K; Shah, S, 2020)
"Aprepitant did not lower incidence of post-ERCP pancreatitis in this preliminary human study. "	( Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial. Branch, MS; Jowell, P; Liddle, R; Obando, J; Poleski, M; Shah, TU, 2012)

Excerpt	Reference
"Aprepitant treatment normalized all parameters compared to cisplatin treated group."	( A novel effect of Aprepitant: Protection for cisplatin-induced nephrotoxicity and hepatotoxicity. Bayir, Y; Cadirci, E; Halici, Z; Kose, D; Selli, J; Ugan, RA; Un, H, 2020)
"Aprepitant treatment offers an opportunity to target inflammation and mood disorders frequently co-existing in chronic HIV infection."	( Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV. Douglas, SD; Evans, DL; Kinder, A; Pappa, V; Rappaport, J; Spitsin, S, 2021)
"Aprepitant treatment resulted in decreased plasma SP levels and affected 176 plasma proteins (56 after FDR) and several metabolic pathways, including inflammation and lipid metabolism."	( Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. Barrett, JS; Douglas, SD; Evans, DL; Kim, D; Pappa, V; Spitsin, S; Taylor, D; Tebas, P, 2017)
"Aprepitant treatment had no effect on PTSD symptoms or subjective or physiological responses to stress or alcohol cues. "	( The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study. Diamond, CA; George, DT; Heilig, M; Hommer, DW; Kwako, LE; Momenan, R; Schwandt, ML; Shaham, Y; Sinha, R; Spagnolo, PA, 2015)
"Aprepitant treatment was associated with significant decreases of median within patient change in percentages of CD4(+) T cells expressing programmed death 1 (-4.8%; P = 0.04), plasma substance P (-34.0 pg/ml; P = 0.05) and soluble CD163 (-563 ng/ml; P = 0.02), with no significant changes in the placebo arm."	( Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. Barrett, JS; Catalano, R; Douglas, SD; Elci, O; Evans, DL; Kim, D; Korelitz, JJ; Spitsin, S; Tebas, P; Tuluc, F; Wagner, W; Winters, A, 2015)
"Aprepitant-treated patients had decreased numbers of CD4(+) programmed death 1-positive cells and decreased plasma levels of substance P and soluble CD163, suggesting that blockade of the neurokinin 1 receptor pathway has a role in modulating monocyte activation in HIV infection."	( Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. Barrett, JS; Catalano, R; Douglas, SD; Elci, O; Evans, DL; Kim, D; Korelitz, JJ; Spitsin, S; Tebas, P; Tuluc, F; Wagner, W; Winters, A, 2015)
"Pretreatment with aprepitant successfully ameliorated and improved all biochemical and molecular parameters induced by DIC."	( Involvement of NOX-4/JAK/STAT pathway in the protective effect of aprepitant against diclofenac-induced renal toxicity. Hafez, HM; Mohamed, MZ; Rifaai, RA; Waz, S, 2022)
"Treatment with aprepitant and its vehicle alone resulted in a potentiating of the infiltration of nickel reactions compared with test reactions obtained after no treatment (1147 + 423 mm(3) and 1427 + 566 mm(3) vs 683 +202 mm(3)) (p = 0.03)."	( Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study. Edvinsson, L; Wallengren, J, 2014)
"Treatment with aprepitant (p < 0.0001), male gender (p = 0.023), cisplatin dose <80 mg/m(2) (p = 0.001), age >or=65 years (p = 0.021), and five or more alcoholic drinks per week (p = 0.027) were all significantly associated with improved complete response. "	( Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Aapro, M; Carides, AD; Hesketh, PJ; Street, JC, 2010)
"Treatment with aprepitant (P < 0.0001), older age (P = 0.006), ethanol use (P = 0.0048), and no history of morning sickness (P = 0.0007) were all significantly associated with reduced likelihood of emesis. "	( Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Carides, AD; Street, JC; Warr, DG, 2011)
"Pre-treatment with aprepitant did not increase adverse events including constipation and elevation of alanine transaminase."	( [Efficacy and safety of aprepitant in patients with breast cancer]. Aogi, K; Eguchi, H; Hara, F; Kiyoto, S; Matsuhisa, T; Osumi, S; Oze, I; Tagashira, H; Takabatake, D; Takahashi, M; Takashima, S, 2011)
"Pre-treatment with aprepitant (200 mg) significantly enhanced ratings of oxycodone subjective effects related to euphoria and liking and doubled the street value estimates for the highest test doses of oxycodone by both routes."	( Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Heilig, M; Henderson, P; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2013)
"Treatment with aprepitant (10(-6) M) inhibited infection of macrophages with the AZT-resistant viruses (A018, A012) by 0.7 log(10)."	( Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. Douglas, SD; Ho, WZ; Lai, JP; Tebas, P; Tuluc, F; Wang, X, 2007)

Excerpt	Reference
" A potential side effect is neurotoxicity, often manifesting as confusion, hallucination, or seizure."	( Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH, 2008)
" In the previous five cycles of ifosfamide, carboplatin, and etoposide, the patient had no problems with the neurotoxic adverse effects associated with ifosfamide use."	( Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Jarkowski, A, 2008)
" The literature review was performed using Medline with the following search terms: adverse events, aprepitant, chemotherapy, CYP3A4, MK-0869, neurokinin(1) receptor antagonist, safety and tolerability."	( Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Herrstedt, J; Ruhlmann, CH, 2011)
" Pre-treatment with aprepitant did not increase adverse events including constipation and elevation of alanine transaminase."	( [Efficacy and safety of aprepitant in patients with breast cancer]. Aogi, K; Eguchi, H; Hara, F; Kiyoto, S; Matsuhisa, T; Osumi, S; Oze, I; Tagashira, H; Takabatake, D; Takahashi, M; Takashima, S, 2011)
" The rates of adverse drug events (ADEs) did not significantly differ between groups."	( Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Oishi, R; Sakurai, A; Takenaka, K; Teshima, T; Uchida, M, 2013)
" The frequencies of adverse drug events (ADEs) were not significantly different between two groups."	( Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Muta, T; Oishi, R; Sakurai, A; Shiratsuchi, M; Suetsugu, K; Takenaka, K; Teshima, T; Uchida, M, 2013)
" In general, NK-1 receptor antagonists are safe and well tolerated."	( Safety of neurokinin-1 receptor antagonists. Coveñas, R; Muñoz, M, 2013)
"A search was carried out in Medline using the following terms: adverse events, aprepitant, casopitant, clinical trials, CP-122,721, ezlopitant, fosaprepitant, NK-1 receptor antagonists, randomized, safety, side effects, tolerability and vofopitant."	( Safety of neurokinin-1 receptor antagonists. Coveñas, R; Muñoz, M, 2013)
" Rates of other frequently observed adverse drug events were similar between groups."	( Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Muta, T; Nagata, K; Oishi, R; Sakurai, A; Shiratsuchi, M; Suetsugu, K; Takenaka, K; Teshima, T; Uchida, M, 2013)
" Of the 460 cycles, adverse events, drug-related adverse events, and serious adverse events occurred in 179 (38."	( Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Bae, DS; Choi, CH; Kim, BG; Kim, HJ; Kim, MK; Kim, TJ; Lee, JW; Lee, YY; Park, JY; Yoon, A, 2014)
"Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC."	( Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan. Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M, 2014)
" Incidence and severity of nausea were assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) and a subjective rating scale completed by patients."	( Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S, 2014)
" The reported adverse drug reactions were hiccups (13."	( Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S, 2014)
" The most common adverse reactions were constipation and fatigue (reported by three patients each)."	( Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. Abe, M; Furuya, K; Hasegawa, K; Hirashima, Y; Itamochi, H; Ito, K; Kai, K; Kuritani, K; Matoda, M; Nasu, K; Otsuki, T; Sato, S; Takano, M; Takeshima, N; Terao, K; Tsubamoto, H, 2014)
" We recently reported increased infusion site adverse events (ISAE) in a cohort of breast cancer patients receiving chemotherapy with doxorubicin and cyclophosphamide (AC)."	( An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Anderson, KJ; Grendahl, DC; Hegerova, LT; Hilger, CR; Leal, AD; Loprinzi, CL; Seisler, DK; Sorgatz, KM, 2015)
"Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse impact on patient health-related quality of life and that can potentially undermine the effectiveness of chemotherapy."	( Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Aapro, M; Carides, A; Rapoport, BL; Schmoll, HJ; Warr, D; Zhang, L, 2015)
" There were no grade 3 or 4 adverse events."	( Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A, 2016)
" The overall incidence of adverse events was similar between the two treatment groups (p > ."	( Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017)
" The most common adverse event was constipation."	( Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study. Chen, YX; Chen, ZD; Cheng, Y; Dang, CX; Dong, J; Han, BH; Hu, B; Li, BL; Li, JL; Liu, B; Lu, JG; Qin, SK; Shi, JH; Shu, YQ; Sun, XC; Wang, D; Wang, HB; Wang, KM; Wang, QM; Wu, Q; Yang, LQ; Zhang, HL; Zhang, QY; Zhang, ZH, 2017)
"An eight-year long case series follow-up study with pediatric bone cancer patients was conducted to compare the occurrence of adverse events associated with aprepitant with official sources of drug information (manufacturer's leaflet, clinical trials, and European Medicines Agency leaflet)."	( Adverse events associated with aprepitant pediatric bone cancer patients. da Silva Ries, SA; Ferreira, MAP; Meneses, CF; Michalowski, MB; Moreira, LB; Okumura, LM, 2019)
"Two open-label, randomized, two-way crossover studies evaluated treatment-emergent adverse events (TEAEs) in 200 healthy subjects."	( Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. Clendeninn, N; Cravets, M; Keller, MR; Lauw, M; Manhard, K; Ottoboni, T; Quart, B, 2018)
" No HTX-019 recipients had infusion-site adverse events, versus 15 (8%) fosaprepitant recipients."	( Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. Clendeninn, N; Cravets, M; Keller, MR; Lauw, M; Manhard, K; Ottoboni, T; Quart, B, 2018)
"Fosaprepitant, an intravenous neurokinin-1 receptor antagonist for chemotherapy-induced nausea and vomiting, contains polysorbate 80, which is associated with infusion-site adverse events (ISAEs) and hypersensitivity systemic reactions (HSRs)."	( Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study. Boccia, R; Clendeninn, N; Geller, RB; Ottoboni, T, 2019)
" Electronic medical records of patients receiving HTX-019 were queried for nursing and medical documentation associated with infusion-site adverse events (ISAEs)."	( Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review. Walton, GD, 2019)
" No clinically significant ISAEs or adverse events associated with HTX-019 were reported."	( Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review. Walton, GD, 2019)
"Chemotherapy-induced nausea and vomiting (CINV) is a distressing treatment side-effect that could negatively affect children's quality of life (QoL)."	( Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma. Beneduce, G; Buffardi, I; Buffardi, S; Giagnuolo, G; Marra, N; Menna, G; Parasole, R; Petruzziello, F; Rossi, F; Tortora, C, 2019)
" This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified."	( Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis. Calcanes, G; Vacirca, JL, )
" These adverse events may be so severe that they impair the patient's compliance with the treatment or even cause its discontinuation."	( Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib. Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB, 2020)
" The standard treatment for newly diagnosed AML is chemotherapy consisting of cytosine arabinoside (Ara-C) and anthracyclines with disappointing clinical outcomes and severe adverse effects, such as symptomatic bradycardia, neurotoxicity."	( Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo. Cheng, X; Fu, C; Huang, F; Jia, X; Meng, Y; Shao, G; Wang, L; Wang, T; Wang, X; Wu, H; Yang, T, 2020)
" The primary endpoint was the rate of adverse events (AEs), including drug related AEs and serious AEs (SAEs)."	( Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. Cai, K; Cheng, G; Fang, J; Hu, X; Huang, J; Li, J; Li, W; Liao, W; Liu, H; Liu, X; Ouyang, Q; Wang, D; Wang, X; Wu, L; Xu, H; Xu, N; Yang, N; Yang, Y; Ye, S; Zhang, H; Zhang, L; Zhang, Y; Zhao, Q; Zheng, J; Zhong, D; Zhong, M; Zhong, W, 2020)
"Especially as a combination treatment, aprepitant is safe and efficient for preventing CINV in patients receiving highly emetogenic chemotherapy."	( Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. Cai, K; Cheng, G; Fang, J; Hu, X; Huang, J; Li, J; Li, W; Liao, W; Liu, H; Liu, X; Ouyang, Q; Wang, D; Wang, X; Wu, L; Xu, H; Xu, N; Yang, N; Yang, Y; Ye, S; Zhang, H; Zhang, L; Zhang, Y; Zhao, Q; Zheng, J; Zhong, D; Zhong, M; Zhong, W, 2020)
" Aprepitant is administered as an anti-emetic agent in chemotherapy and regarding the inhibitory effect on CYP3A4, aprepitant can increase the risk of ifosfamide adverse effects."	( Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. Mohammadpour, AH; Rahimi, H; Sadeghi, M; Samadi, S; Vazirian, F, 2022)

Excerpt	Reference
"Two studies were conducted to determine whether concomitant administration of aprepitant altered the pharmacokinetic profiles of ondansetron and granisetron, two 5-HT(3)-receptor antagonists commonly used as antiemetic therapy for CINV."	( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003)
" Individual plasma samples were used to estimate area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )), peak plasma concentration, and apparent terminal elimination half-life (t(12)) of both ondansetron and granisetron."	( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003)
"019), with no significant effect on peak concentration at the end of the infusion (360."	( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003)
"Concomitant administration of aprepitant had no clinically significant effect on the mean pharmacokinetic characteristics of either ondansetron or granisetron in these healthy subjects."	( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003)
" The pharmacokinetic profile of docetaxel was assessed over 30 h following docetaxel infusion."	( Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Ahmed, T; Cocquyt, V; de Smet, M; Fedgchin, M; Gottesdiener, KM; Hande, K; Majumdar, A; Murphy, MG; Nygren, P; Panebianco, D; Petty, KJ; van Belle, S; van Dyck, K, 2005)
" The corresponding harmonic mean half-life values were 10."	( Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Ahmed, T; Cocquyt, V; de Smet, M; Fedgchin, M; Gottesdiener, KM; Hande, K; Majumdar, A; Murphy, MG; Nygren, P; Panebianco, D; Petty, KJ; van Belle, S; van Dyck, K, 2005)
" Blood for pharmacokinetic evaluations was collected through 168 hours after palonosetron administration on days 1 and 15; safety was monitored through day 22."	( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005)
" With and without aprepitant coadministration, respectively, mean plasma elimination half-life was 40 hours and 43 hours (difference: -3."	( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005)
"These results indicate no significant differences in pharmacokinetic parameters for palonosetron between the two treatments, and suggest that palonosetron can be safely coadministered with aprepitant with no alterations in the expected safety profile and no dosage adjustment necessary."	( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005)
" Pharmacokinetic parameters after a single oral dose of aprepitant 240 mg were measured in eight patients with end-stage renal disease (ESRD) requiring haemodialysis, eight patients with severe renal insufficiency (SRI [24-hour creatinine clearance <30 mL/min/1."	( Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Aiyer, KJ; Bergman, AJ; Bradstreet, TE; Busillo, J; Constanzer, M; Fosbinder, T; Hickey, L; Huskey, SE; Majumdar, A; Marbury, T; Petty, KJ; Swan, S, 2005)
" Aprepitant pharmacokinetic parameters in ESRD patients were clinically similar when haemodialysis was initiated at 4 hours or 48 hours after aprepitant administration."	( Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Aiyer, KJ; Bergman, AJ; Bradstreet, TE; Busillo, J; Constanzer, M; Fosbinder, T; Hickey, L; Huskey, SE; Majumdar, A; Marbury, T; Petty, KJ; Swan, S, 2005)
" Complete pharmacokinetic data of vinorelbine administered alone and with the aprepitant antiemetic regimen were obtained in 12 patients."	( Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. de Bruijn, P; de Wit, R; Freedman, SJ; Gambale, JJ; Li, S; Loos, WJ; Murphy, GM; Van Dyck, K; van Noort, C; Verweij, J, 2007)
"To develop a population pharmacokinetic model of aprepitant and dexamethasone in Japanese patients with cancer, explore the factors that affect the pharmacokinetics of aprepitant, and evaluate the effect of aprepitant on the clearance of intravenous dexamethasone."	( Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Awata, H; Hashimoto, Y; Katayama, M; Kitagawa, J; Kodama, Y; Miyata, Y; Nakade, S; Ohno, T, 2008)
"A pharmacokinetic model for aprepitant has been developed that incorporates body weight, age, ALT, BUN and aprepitant dose to predict the CL/F."	( Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Awata, H; Hashimoto, Y; Katayama, M; Kitagawa, J; Kodama, Y; Miyata, Y; Nakade, S; Ohno, T, 2008)
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)
" Such data include physicochemical and in vitro drug properties, biorelevant solubility and dissolution, and in vivo pre-clinical and clinical pharmacokinetic data."	( Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. Bolger, MB; Fraczkiewicz, G; Lukacova, V; Parrott, N, 2009)
"This review examines the chemical development of fosaprepitant, its pharmacokinetic properties, approved uses and potential applications."	( Pharmacokinetic evaluation of fosaprepitant dimeglumine. Colon-Gonzalez, F; Kraft, WK, 2010)
" Clinical studies have demonstrated pharmacokinetic bioequivalence of aprepitant 125 mg to fosaprepitant 115 mg, as well as comparable efficacy in prevention of acute and delayed emesis following the first day of chemotherapy regimens."	( Pharmacokinetic evaluation of fosaprepitant dimeglumine. Colon-Gonzalez, F; Kraft, WK, 2010)
" Standard pharmacokinetic parameters were calculated and nonparametric testing was applied to assess the differences between aprepitant and placebo treatment."	( The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Burhenne, J; Egerer, G; Eisenlohr, K; Gronkowski, M; Mikus, G; Riedel, KD, 2010)
" In addition, AUC and terminal elimination half-life were not changed by aprepitant."	( The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Burhenne, J; Egerer, G; Eisenlohr, K; Gronkowski, M; Mikus, G; Riedel, KD, 2010)
" No dosage adjustment was necessary, and administration of aprepitant in HSCT at the prescribed dosage of 125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT was well tolerated with no significant changes in CY pharmacokinetic parameters."	( Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. Bubalo, JS; Cherala, G; Maziarz, R; McCune, JS; Munar, MY; Tse, S, 2012)
" The half-life and clearance of dinaciclib were similar, with or without aprepitant."	( Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Bannerji, R; Kantesaria, B; Mita, M; Poon, J; Shapiro, GI; Small, K; Statkevich, P; Tzontcheva, A; Zhang, D; Zhu, Y, 2012)
" Due to the low aqueous solubility of the active substance the product development has been focused on decreasing the particle size of the active compound down to the submicron range in order to overcome this disadvantageous pharmacokinetic property."	( Novel continuous flow technology for the development of a nanostructured aprepitant formulation with improved pharmacokinetic properties. Angi, R; Darvas, F; Filipcsei, G; Glavinas, H; Heltovics, G; Ordasi, B; Ötvös, Z; Solymosi, T, 2014)
" Subsequently, a pharmacokinetic study was performed using liquid chromatography-tandem mass spectrometry."	( Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-β-cyclodextrin complex. Chen, G; Li, M; Ren, L; Wei, P; Zhou, Y, 2014)
" The solid dispersions were characterized by dissolution, FTIR, XRPD, DSC, SEM and pharmacokinetic studies in rats."	( Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®. Cheng, G; Gao, Y; Liu, J; Liu, Y; Ma, N; Piao, H; Tang, B; Zou, M, 2015)
" At a test dose of 20mg/kg, the pharmacokinetic study of APPT-Ms showed that it accorded with first-order kinetics in mice, and its AUC value was higher than the pure AAPT about 6 times."	( 15-hydroxystearate micelles for the delivery of aprepitant: Preparation, characterization, pharmacokinetics and tissue distribution in mice. Ge, J; Kong, H; Liu, H; Pan, H; Wang, M, 2021)
" The current pharmacokinetic study was developed to investigate whether this extemporaneous oral suspension offers an appropriate treatment option."	( A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. de Vos-Kerkhof, E; Enters-Weijnen, CF; Hanff, LM; Huitema, ADR; Lalmohamed, A; Lange, R; Nijstad, AL; Rosing, H; Tibben, MM; Tissing, WJE; van de Wetering, MD; Zwaan, CM, 2023)
" Pharmacokinetic analyses were performed using nonlinear mixed effects modelling."	( A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. de Vos-Kerkhof, E; Enters-Weijnen, CF; Hanff, LM; Huitema, ADR; Lalmohamed, A; Lange, R; Nijstad, AL; Rosing, H; Tibben, MM; Tissing, WJE; van de Wetering, MD; Zwaan, CM, 2023)
" An integrated dexamethasone and aprepitant pharmacokinetic model was developed using non-linear mixed effects modelling in order to investigate the effect of aprepitant administration on dexamethasone CL."	( Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. de Vos-Kerkhof, E; Enters-Weijnen, CF; Huitema, ADR; Lalmohamed, A; Nijstad, AL; Rosing, H; Tibben, MM; Tissing, WJE; van de Wetering, MD; Zwaan, CM, 2022)
"A population pharmacokinetic approach was applied to analyze data obtained in 42 patients at cycle 1 (without aprepitant) and cycle 2 (with aprepitant for 34 of them)."	( Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide. Allal, B; Chaltiel, L; Chatelut, E; Chevreau, C; Filleron, T; Firmin, N; Lambert, M; Mseddi, M; Toulmonde, M; Valentin, T; Yakoubi, M, 2023)
"A previously published pharmacokinetic model including a time-dependency process well fit the data."	( Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide. Allal, B; Chaltiel, L; Chatelut, E; Chevreau, C; Filleron, T; Firmin, N; Lambert, M; Mseddi, M; Toulmonde, M; Valentin, T; Yakoubi, M, 2023)

Excerpt	Reference
"The implications of chemotherapeutic drug-drug interactions can be serious and thus need to be addressed."	( Aprepitant: drug-drug interactions in perspective. Aapro, MS; Walko, CM, 2010)
"Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5-HT(3) receptor antagonist, are used to prevent chemotherapy-induced nausea and vomiting."	( Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. Caro, L; Jin, B; Marbury, TC; Murphy, G; Ngo, PL; Panebianco, D; Shadle, CR; Valentine, J, 2011)
" We conducted a double-blind, placebo-controlled phase III cross-over study that compared aprepitant to placebo combined with standard antiemetic prophylaxis (a 5HT3-RA and dexamethasone) in patients receiving 5 days of cisplatin combination chemotherapy for testicular cancer."	( Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin co Albany, C; Brames, MJ; Einhorn, LH; Fausel, C; Johnson, CS; Picus, J, 2012)
"There was a significant improvement in CR rate with aprepitant combined with a 5HT3-RA and dexamethasone."	( Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin co Albany, C; Brames, MJ; Einhorn, LH; Fausel, C; Johnson, CS; Picus, J, 2012)
" This study aimed to retrospectively evaluate the efficacy of repeated administrations of 3-day courses of aprepitant according to the cisplatin split regimen (20mg/m² day, days 1-4, 22-25, 43-46) in combination with radiation."	( [Evaluation of aprepitant as a prophylactic antiemetic in the Cisplatin split regimen combined with radiation for patients with head and neck cancer]. Endo, K; Enokida, T; Ichida, Y; Ishiki, H; Izumi, K; Saitoh, S; Suzuki, S; Tahara, M; Yoshida, M, 2014)
" Oral olanzapine (5 mg) was administered with triplet therapy a day prior to cisplatin administration and on days 1-5."	( Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A, 2016)
"Preventive use of olanzapine combined with triplet therapy gives better results than those from previously reported studies of triplet therapy."	( Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A, 2016)
" This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug-drug interactions of aprepitant/fosaprepitant and implications for clinical practice."	( Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. Carbone, A; Dushenkov, A; Jungsuwadee, P; Kalabalik, J, 2017)
" In patients who receive highly emetogenic chemotherapy, aprepitant, an NK1-receptor antagonist, is combined with ondansetron and dexamethasone."	( Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy. Desar, IME; Kramers, C; Lankheet, AG; Schoffelen, R; van der Hoeven, JJM; van Herpen, CML, 2018)
"The aim of this study was to evaluate aprepitant in combination with palonosetron as compared to palonosetron alone for the prevention of postoperative nausea and vomiting (PONV) in female patients receiving fentanyl- based intravenous patient-controlled analgesia (IV-PCA)."	( Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Chung, JW; Han, YM; Jun, MR; Kim, SI; Kim, YJ; Yoo, JH, 2018)
"Aprepitant combined with palonosetron did not reduce the incidence of PONV as compared to palonosetron alone within 24 h of surgery in women receiving fentanyl-based IV-PCA."	( Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Chung, JW; Han, YM; Jun, MR; Kim, SI; Kim, YJ; Yoo, JH, 2018)
"Polypharmacy of elderly oncology patients and fragmented medication management are well-known risk factors for drug-drug interactions (DDIs)."	( Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019)
"Preventive use of OLZ combined with standard triplet therapy had promising activity with manageable safety, suggesting that this combination could be an effective standard treatment option for patients with AUC ≥4 mg/mL/min CBDCA combination therapy."	( Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. Abe, M; Arai, T; Fujita, Y; Hayasaki, Y; Iihara, H; Kado, N; Mori, M; Morishige, KI; Murase, S; Nakamura, K; Sakurai, M; Shimaoka, R; Shimokawa, M; Suzuki, A; Takenaka, M; Yamamoto, S, 2020)
"25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4)."	( Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. Ahn, JS; An, HJ; Kang, JH; Kim, GM; Kim, HJ; Kim, JY; Koo, DH; Kwon, JH; Lee, H; Lee, YG; Park, KU; Seol, YM; Sohn, J; Song, H; Yang, JH; Yun, HJ, 2020)
" This study aimed to evaluate the antiemetic efficacy of palonosetron (PALO) over granisetron (GRA) in combination with dexamethasone for multiple highly emetogenic chemotherapy drugs (HEC), especially in chemotherapy regimens in Egyptian breast cancer patients and cisplatin-based regimens in other diseases."	( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy. A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021)
" All patients received dexamethasone in combination with the 5-HT3 receptor antagonist."	( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy. A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021)
"Palonosetron, combined with dexamethasone, is more effective than granisetron and dexamethasone combination against both acute and delayed emesis induced by highly emetogenic chemotherapy (HEC) cisplatin-based protocols and the combination of cyclophosphamide and anthracyclines (AC)."	( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy. A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021)
"The purpose of the present work was to evaluate in silico drug-drug interaction (DDI) potential between BCa chemotherapeutic drugs and antiemetic agents."	( Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. Deb, S; Hopefl, R, 2023)
"The Drug-Drug Interaction™ module of GastroPlus™ was employed to assess CYP-related interactions between antiemetic and anticancer therapy combinations."	( Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. Deb, S; Hopefl, R, 2023)
" Moderate to no interactions were observed with ondansetron, aprepitant, rolapitant, and dexamethasone in combination with anticancer agents."	( Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. Deb, S; Hopefl, R, 2023)

Excerpt	Reference
" Study 1 evaluated the bioavailability of the capsules and estimated the effect of food."	( Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Bergman, AJ; Bradstreet, TE; Butler, K; Constanzer, M; Crumley, TM; De Lepeleire, I; Goldberg, MR; Greenberg, HE; Hickey, L; Howard, L; Knops, A; Majumdar, AK; Michiels, N; Panebianco, D; Petty, KJ; Rothenberg, PL; Waldman, SA, 2006)
" This drug is well absorbed orally with a t max of about four hours."	( Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Girish, C; Manikandan, S, )
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)
" The bioavailability of this formulation is unknown."	( Stability of an extemporaneous oral liquid aprepitant formulation. Dupuis, LL; Lingertat-Walsh, K; Walker, SE, 2009)
" Although dissolution is the primary limitation to the rate of absorption for micronized aprepitant, some permeability restrictions are revealed for the nanosized formulation."	( Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Dressman, JB; Jantratid, E; Kesisoglou, F; Reppas, C; Shono, Y, 2010)
" The results indicate that aprepitant is well absorbed and does not auto-induce its metabolism."	( Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. Bubalo, JS; Cherala, G; Maziarz, R; McCune, JS; Munar, MY; Tse, S, 2012)
" The innovator Emend® is a formulation incorporating drug nanoparticles with good bioavailability (~67%)."	( Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Ansari, KA; Dhawan, S; Kaul, NS; Krishnamurthy, T; Kumar, D; Pillai, R; Ridhurkar, DN, 2013)
"These studies established that cyclodextrin complexation may provide another viable and cost effective option for enhancing solubility and bioavailability of APR."	( Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties. Ansari, KA; Dhawan, S; Kaul, NS; Krishnamurthy, T; Kumar, D; Pillai, R; Ridhurkar, DN, 2013)
"The oral bioavailability of Aprepitant is limited by poor dissolution of the compound in the gastrointestinal tract which is more prominent in the fasted state resulting in significant positive food effect."	( Novel continuous flow technology for the development of a nanostructured aprepitant formulation with improved pharmacokinetic properties. Angi, R; Darvas, F; Filipcsei, G; Glavinas, H; Heltovics, G; Ordasi, B; Ötvös, Z; Solymosi, T, 2014)
" The bioavailability of the drug complex was comparable to that of Emend."	( Preparation and pharmacokinetic study of aprepitant-sulfobutyl ether-β-cyclodextrin complex. Chen, G; Li, M; Ren, L; Wei, P; Zhou, Y, 2014)
"Solid dispersions are a useful approach to improve the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs)."	( Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus®. Cheng, G; Gao, Y; Liu, J; Liu, Y; Ma, N; Piao, H; Tang, B; Zou, M, 2015)
" Therefore, we aimed to improve solubility as well as permeability that could possibly improve oral bioavailability of APT."	( Aprepitant loaded solid preconcentrated microemulsion for enhanced bioavailability: A comparison with micronized Aprepitant. Kamboj, S; Rana, V; Sharma, R; Singh, K, 2015)
" The data also suggested increase in absorption rate when APT incorporated into SCFG-SEP."	( Formulation optimization of aprepitant microemulsion-loaded silicated corn fiber gum particles for enhanced bioavailability. Kamboj, S; Rana, V, 2016)
" The optimized ODF was evaluated for various physicochemical, mechanical, drug release kinetics and bioavailability studies."	( Development of aprepitant loaded orally disintegrating films for enhanced pharmacokinetic performance. Kamboj, S; Rana, V; Sharma, R; Singh, G, 2016)
"32-fold, and the bioavailability was greatly decreased about 30."	( Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. Darbalaei, S; Han, X; Lu, Y; Qin, Y; Rang, Y; Wang, N; Zhai, X; Zhang, X, 2018)
"The characterization of nanocrystalline active ingredients in multicomponent formulations for the design and manufacture of products with increased bioavailability is often challenging."	( Detailed Morphological Characterization of Nanocrystalline Active Ingredients in Solid Oral Dosage Forms Using Atomic Force Microscopy. Goda, Y; Izutsu, KI; Nanjo, K; Okuda, H; Sakai-Kato, K; Takechi-Haraya, Y, 2019)
" While nano-sizing aprepitant improves its in vivo performance, intestinal solubility remains a barrier to its bioavailability and thus aprepitant should be classified as DCS IIb."	( Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states. Box, KJ; Dressman, J; Kostewicz, E; Kuentz, M; Litou, C; Patel, N; Turner, DB, 2019)
" We aimed to determine the bioavailability of this aprepitant suspension relative to the capsule."	( Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. Dupuis, LL; Nathan, PC; Patel, P; Volpe, J; Walker, SE; Zupanec, S, 2019)
" Relative bioavailability was defined as the geometric least squares mean ratio for area under the concentration versus time curve (AUC) from time zero to infinity of the aprepitant suspension versus the capsule."	( Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. Dupuis, LL; Nathan, PC; Patel, P; Volpe, J; Walker, SE; Zupanec, S, 2019)
"Relative bioavailability of the aprepitant suspension was 82."	( Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. Dupuis, LL; Nathan, PC; Patel, P; Volpe, J; Walker, SE; Zupanec, S, 2019)
"With a relative bioavailability of 82."	( Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. Dupuis, LL; Nathan, PC; Patel, P; Volpe, J; Walker, SE; Zupanec, S, 2019)
" The bioavailability of the extemporaneous oral suspension was not significantly different to that of the capsules (P = 0."	( A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. de Vos-Kerkhof, E; Enters-Weijnen, CF; Hanff, LM; Huitema, ADR; Lalmohamed, A; Lange, R; Nijstad, AL; Rosing, H; Tibben, MM; Tissing, WJE; van de Wetering, MD; Zwaan, CM, 2023)
" An adequate exposure to aprepitant in children was yielded and the bioavailability of the extemporaneous suspension was comparable to capsules."	( A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children. de Vos-Kerkhof, E; Enters-Weijnen, CF; Hanff, LM; Huitema, ADR; Lalmohamed, A; Lange, R; Nijstad, AL; Rosing, H; Tibben, MM; Tissing, WJE; van de Wetering, MD; Zwaan, CM, 2023)
" This study focused on improving its permeability and solubility in order to improve the oral bioavailability of aprepitant."	( Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability. Ao, W; Bai, M; Li, S; Li, Y; Liu, J; Xiao, Y, 2022)

Excerpt	Reference
" dosing of I to rats and dogs."	( Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Chiu, SH; Dean, BJ; Feeney, WP; Huskey, SE; Luffer-Atlas, D; McGowan, EM, 1999)
" Continued dosing with MK-869 may enhance control of other measures of delayed emesis, such as the use of rescue medication, although confirmation is required before a definitive conclusion may be drawn."	( Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Brestan, E; Bui, B; Carides, AD; De Smet, M; Decramer, ML; Eldridge, K; Evans, JK; Garin, AM; Gertz, BJ; Lichinitser, MR; Michiels, N; Navari, RM; Reinhardt, RR; Riviere, A; Thant, M; Van Belle, S, 2002)
" An important objective of all neuroscience drug discovery and development programs is to establish the correlation between dose, receptor occupancy, and the observed clinical effect (the dose-response relationship)."	( Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. Hargreaves, R, 2002)
" Thus, aprepitant, when dosed as a 5-day regimen, did not interact with a known substrate of the P-glycoprotein transporter."	( Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. Brackett, LE; De Smet, M; Feuring, M; Goldberg, MR; Gottesdiener, KM; Hesney, M; Lee, Y; Majumdar, AK; Michiels, N; Murphy, MG; Orlowski, LH; Petty, KJ; Wehling, M, 2003)
" Repeated dosing with aprepitant over multiple cycles was generally well tolerated."	( The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial Carides, AD; de Wit, R; Elmer, M; Evans, JK; Guoguang-Ma, J; Herrstedt, J; Horgan, KJ; Rapoport, B; Schmidt, C, 2004)
" Because metabolism of some chemotherapeutic agents may involve CYP3A4, the potential inductive effect of the CINV dosing regimen of aprepitant on this metabolic pathway was evaluated using intravenous midazolam, a sensitive probe substrate of CYP3A4."	( Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. Blum, RA; Bradstreet, TE; Evans, JK; Gargano, C; Lee, Y; Majumdar, AK; Petty, KJ; Shadle, CR, 2004)
" The first study evaluated the plasma concentration-occupancy relationships for aprepitant dosed orally at 10, 30, 100, or 300 mg, or placebo (n = 12)."	( Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Antoni, G; Battisti, WP; Bergström, M; Bradstreet, TE; Burns, HD; Constanzer, ML; Eskola, O; Gargano, C; Goldberg, MR; Hargreaves, RJ; Hietala, J; Långström, B; Majumdar, AK; Ogren, M; Petty, KJ; Reines, SA; Scheinin, M; Sciberras, D; Solin, O, 2004)
" Acute and delayed nausea may also be improved by aprepitant when used in combination with a 5-HT3 and dexamethasone prechemotherapy or with daily dosing for 3-5 days following chemotherapy."	( Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Navari, RM, )
" In addition, the dog model was used for optimizing formulation processes in which the nanoparticles were incorporated into solid dosage forms, and for selecting excipients to effectively re-disperse the nanoparticles from the dosage units."	( The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Batra, U; Chen, C; Hettrick, L; Higgins, R; Kwei, G; Landis, E; Loper, A; Lynn, K; Novak, L; Shelukar, S; Storey, D; Thompson, K; Wu, Y, 2004)
"These results indicate no significant differences in pharmacokinetic parameters for palonosetron between the two treatments, and suggest that palonosetron can be safely coadministered with aprepitant with no alterations in the expected safety profile and no dosage adjustment necessary."	( Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK, 2005)
" Therefore, no dosage adjustment of aprepitant is warranted in SRI or ESRD patients."	( Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Aiyer, KJ; Bergman, AJ; Bradstreet, TE; Busillo, J; Constanzer, M; Fosbinder, T; Hickey, L; Huskey, SE; Majumdar, A; Marbury, T; Petty, KJ; Swan, S, 2005)
" A positron emission tomography (PET) study was also performed in normal subjects to determine the relationship between neurokinin(1) receptor occupancy and aprepitant plasma concentrations in dosing regimens relevant to the trials."	( Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Ball, W; Beebe, K; Hargreaves, R; Hietala, J; Keller, M; Lines, C; Liu, G; Montgomery, S; Morrison, M; Reines, S; Snavely, D, 2006)
" Results from the PET study indicated that the aprepitant dosing regimens provided continuously high levels of neurokinin(1) receptor blockade over 8 weeks."	( Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Ball, W; Beebe, K; Hargreaves, R; Hietala, J; Keller, M; Lines, C; Liu, G; Montgomery, S; Morrison, M; Reines, S; Snavely, D, 2006)
" Further study is needed to clarify the use of fosaprepitant for the prevention of CINV, and to clarify optimal dosing regimens that may be appropriate substitutes for oral aprepitant."	( Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari, RM, 2007)
" Multiple-day dosing of palonosetron plus dexamethasone was safe and effective for prevention of emesis induced by 5-day cisplatin-based chemotherapy."	( Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Bajetta, E; Canova, S; Celio, L; Denaro, A; Gevorgyan, A, )
" Further study is needed to clarify the utility of fosaprepitant in the prevention of CINV and to clarify optimal dosing regimens that may be appropriate substitutes for oral aprepitant."	( Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari, RM, 2008)
" Pharmacokinetics suggest that the adult dosing regimen is appropriate for adolescents."	( Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J, 2009)
" The lack of an oral liquid dosage form is one barrier to its use in children."	( Stability of an extemporaneous oral liquid aprepitant formulation. Dupuis, LL; Lingertat-Walsh, K; Walker, SE, 2009)
" If such drugs reach clinical development and show undesirable variability when dosed with food, improved formulation can help to reduce the food effect and carefully designed in vivo studies in dogs can be a useful guide to clinical formulation development."	( Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects. Bolger, MB; Fraczkiewicz, G; Lukacova, V; Parrott, N, 2009)
" GI parameters (gastric emptying rate and GI fluid volume) were varied according to the dosing conditions."	( Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Dressman, JB; Jantratid, E; Kesisoglou, F; Reppas, C; Shono, Y, 2010)
" The exact dosing regimen for ondansetron and dexamethasone was different in each study."	( Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Carides, AD; Hesketh, PJ; Street, JC; Warr, DG, 2011)
" No dosage adjustment was necessary, and administration of aprepitant in HSCT at the prescribed dosage of 125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT was well tolerated with no significant changes in CY pharmacokinetic parameters."	( Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. Bubalo, JS; Cherala, G; Maziarz, R; McCune, JS; Munar, MY; Tse, S, 2012)
" Aprepitant plasma concentration profiles were comparable for the two dosage forms."	( Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Bormans, G; Butterfield, KL; De Hoon, J; De Lepeleire, I; Declercq, R; Derdelinckx, I; Hamill, T; Hargreaves, RJ; Koole, M; Liu, F; Liu, Y; Mahon, C; Mozley, PD; Murphy, MG; Rosen, LB; Sanabria Bohorquez, SM; Shadle, CR; Tatosian, D; Van Laere, K; Wagner, JA; Xie, W; Zappacosta, P, 2012)
" During cycle 1 and cycle 2, subjects received dinaciclib with aprepitant in one cycle and dinaciclib without aprepitant in the other cycle; aprepitant was administered at a dose of 125 mg orally on day 1 and 80 mg orally on days 2 and 3, along with standard dosing regimens of ondansetron and dexamethasone."	( Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Bannerji, R; Kantesaria, B; Mita, M; Poon, J; Shapiro, GI; Small, K; Statkevich, P; Tzontcheva, A; Zhang, D; Zhu, Y, 2012)
"Patients scheduled to receive cisplatin (≥70 mg/m 2 ) were administered a single IV dose of fosaprepitant dimeglumine (150 mg) on day 1 or a 3-day dosing regimen of oral aprepitant (day 1:125 mg, days 2 and 3:80 mg) with standard doses of ondansetron and dexamethasone."	( A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. Carides, AD; Desai, CJ; Gangadharan, VP; Maru, A; Mohapatra, RK, )
" Plasma concentration of oxycodone and its metabolites were measured up to 8 hours after administration as follows: on day 1, CR oxycodone was administered alone; on day 2, CR oxycodone was administered with aprepitant (125 mg, at the same time of oxycodone dosing in the morning)."	( Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. Chayahara, N; Fujiwara, Y; Imamura, Y; Kiyota, N; Minami, H; Mukohara, T; Shimada, T; Toyoda, M, 2014)
" Although warfarin dosage was steadily increased over the four subsequent cycles of chemotherapy, therapeutic target range was not recovered."	( Persistent drug interaction between aprepitant and warfarin in patients receiving anticancer chemotherapy. Hisaka, A; Ohno, Y; Suzuki, H; Yamada, M; Yamaguchi, R, 2014)
" Ondansetron was dosed per the product label for paediatric use or local standard of care."	( Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. DiCristina, C; Green, S; Kang, HJ; Loftus, S; Taylor, A; Zwaan, CM, 2015)
"There were no significant changes in the plasma viremia or CD4(+) T cells during the dosing period."	( Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. Barrett, JS; Catalano, R; Douglas, SD; Elci, O; Evans, DL; Kim, D; Korelitz, JJ; Spitsin, S; Tebas, P; Tuluc, F; Wagner, W; Winters, A, 2015)
" These alterations did not translate into adverse outcomes and/or necessitate dosing adjustments."	( Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. Carbone, A; Dushenkov, A; Jungsuwadee, P; Kalabalik, J, 2017)
" Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy."	( Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT). Ades, S; Ashikaga, T; Blackstock, W; Halyard, M; Heimann, R; Kumar, S; Wilson, K, 2017)
" Solid-state nuclear magnetic resonance (ssNMR) spectroscopy plays a critical role in the characterization of solid dosage forms due to its capabilities of chemical identification, quantification, and structural elucidation at a molecular level."	( Three-Dimensional NMR Spectroscopy of Fluorinated Pharmaceutical Solids under Ultrafast Magic Angle Spinning. Lu, X; McNevin, MJ; Skomski, D; Su, Y; Thompson, KC; Xu, W, 2019)
"Using patient-derived glioblastoma stem cell (GSC) cultures from 15 GBM patients, we described stem cell properties of individual cultures, determined the dose-response relationships of the drugs in the CUSP9, and assessed the efficacy the CUSP9 combination with TMZ in concentrations clinically achievable."	( The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019)
" PONV incidence, complete response, 80 mg aprepitant combined with dexamethasone and ondansetron, vomiting, nausea, and analgesic dose-response were the main outcomes measured."	( The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. Chen, X; He, H; Hu, W; Liao, Y; Liu, W; Liu, Y; Pan, Z; Wang, X; Zheng, F; Zhong, H, 2023)
" No statistically significant difference between the dose-response of analgesics was identified (mean difference: -1."	( The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis. Chen, X; He, H; Hu, W; Liao, Y; Liu, W; Liu, Y; Pan, Z; Wang, X; Zheng, F; Zhong, H, 2023)

Role	Description
antidepressant	Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
antiemetic	A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
peripheral nervous system drug	A drug that acts principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system.
neurokinin-1 receptor antagonist	An antagonist at the neurokinin-1 receptor.
substance P receptor antagonist	An antagonist at the substance P receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
triazoles	An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
morpholines	Any compound containing morpholine as part of its structure.
cyclic acetal	An acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
(trifluoromethyl)benzenes	An organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	26.8325	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	26.6032	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
GALC protein	Homo sapiens (human)	Potency	0.6310	28.1838	28.1838	28.1838	AID1159614
TDP1 protein	Homo sapiens (human)	Potency	19.9867	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	11.5708	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	29.0533	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	26.6032	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	10.0151	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	22.0412	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.6918	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	27.1824	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	29.6067	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	12.0652	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	25.8482	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	29.8470	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	9.4392	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	26.3828	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743078; AID743091
G	Vesicular stomatitis virus	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	15.4871	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	31.6679	0.0010	24.5048	61.6448	AID743215; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	33.4889	0.0010	19.4141	70.9645	AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	28.3398	0.0237	23.2282	63.5986	AID743222; AID743223
caspase-3	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	29.8493	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	29.8493	0.0016	28.0151	77.1139	AID1259385
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	26.8325	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	61.9315	0.0391	47.5451	146.8240	AID1224845; AID1224896
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	10.0741	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	33.4889	0.0420	27.3789	61.6448	AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	33.4889	0.0006	27.2152	1,122.0200	AID743202
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	29.8493	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	11.9877	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	30.7337	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	29.8493	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.0460	0.0001	1.7536	10.0000	AID301062
Substance-P receptor	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0000	0.0952	6.8130	AID1817659; AID208406; AID208423; AID208440; AID208587; AID270514; AID271466; AID301059; AID342286; AID779964
Substance-P receptor	Homo sapiens (human)	Ki	0.0013	0.0000	0.7936	8.7470	AID1064184; AID715707; AID715708
Neuromedin-K receptor	Homo sapiens (human)	Ki	0.4541	0.0002	0.0543	0.9250	AID715706
Substance-P receptor	Meriones unguiculatus (Mongolian gerbil)	IC50 (µMol)	0.0001	0.0001	0.0063	0.0126	AID1237291
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Substance-P receptor	Homo sapiens (human)	Kd	0.0083	0.0000	0.0054	0.0166	AID715902
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
aggressive behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of leukocyte migration	Substance-P receptor	Homo sapiens (human)
angiotensin-mediated drinking behavior	Substance-P receptor	Homo sapiens (human)
inflammatory response	Substance-P receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Substance-P receptor	Homo sapiens (human)
tachykinin receptor signaling pathway	Substance-P receptor	Homo sapiens (human)
long-term memory	Substance-P receptor	Homo sapiens (human)
associative learning	Substance-P receptor	Homo sapiens (human)
detection of abiotic stimulus	Substance-P receptor	Homo sapiens (human)
response to ozone	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell migration	Substance-P receptor	Homo sapiens (human)
response to auditory stimulus	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell migration	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, cholinergic	Substance-P receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Substance-P receptor	Homo sapiens (human)
response to estradiol	Substance-P receptor	Homo sapiens (human)
response to progesterone	Substance-P receptor	Homo sapiens (human)
response to nicotine	Substance-P receptor	Homo sapiens (human)
operant conditioning	Substance-P receptor	Homo sapiens (human)
sperm ejaculation	Substance-P receptor	Homo sapiens (human)
eating behavior	Substance-P receptor	Homo sapiens (human)
positive regulation of vascular permeability	Substance-P receptor	Homo sapiens (human)
response to ethanol	Substance-P receptor	Homo sapiens (human)
positive regulation of action potential	Substance-P receptor	Homo sapiens (human)
positive regulation of blood pressure	Substance-P receptor	Homo sapiens (human)
positive regulation of ossification	Substance-P receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Substance-P receptor	Homo sapiens (human)
positive regulation of hormone secretion	Substance-P receptor	Homo sapiens (human)
behavioral response to pain	Substance-P receptor	Homo sapiens (human)
regulation of smooth muscle cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of lymphocyte proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Substance-P receptor	Homo sapiens (human)
positive regulation of stress fiber assembly	Substance-P receptor	Homo sapiens (human)
response to electrical stimulus	Substance-P receptor	Homo sapiens (human)
smooth muscle contraction involved in micturition	Substance-P receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Substance-P receptor	Homo sapiens (human)
positive regulation of flagellated sperm motility	Substance-P receptor	Homo sapiens (human)
tachykinin receptor signaling pathway	Neuromedin-K receptor	Homo sapiens (human)
positive regulation of heart rate	Neuromedin-K receptor	Homo sapiens (human)
response to estradiol	Neuromedin-K receptor	Homo sapiens (human)
regulation of dopamine metabolic process	Neuromedin-K receptor	Homo sapiens (human)
response to cocaine	Neuromedin-K receptor	Homo sapiens (human)
positive regulation of blood pressure	Neuromedin-K receptor	Homo sapiens (human)
regulation of feeding behavior	Neuromedin-K receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Neuromedin-K receptor	Homo sapiens (human)
positive regulation of flagellated sperm motility	Neuromedin-K receptor	Homo sapiens (human)
protein phosphorylation	cGMP-dependent protein kinase 1	Homo sapiens (human)
neuron migration	cGMP-dependent protein kinase 1	Homo sapiens (human)
signal transduction	cGMP-dependent protein kinase 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	cGMP-dependent protein kinase 1	Homo sapiens (human)
spermatid development	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of inositol phosphate biosynthetic process	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of glutamate secretion	cGMP-dependent protein kinase 1	Homo sapiens (human)
dendrite development	cGMP-dependent protein kinase 1	Homo sapiens (human)
cGMP-mediated signaling	cGMP-dependent protein kinase 1	Homo sapiens (human)
cerebellum development	cGMP-dependent protein kinase 1	Homo sapiens (human)
actin cytoskeleton organization	cGMP-dependent protein kinase 1	Homo sapiens (human)
forebrain development	cGMP-dependent protein kinase 1	Homo sapiens (human)
positive regulation of circadian rhythm	cGMP-dependent protein kinase 1	Homo sapiens (human)
regulation of GTPase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
collateral sprouting	cGMP-dependent protein kinase 1	Homo sapiens (human)
relaxation of vascular associated smooth muscle	cGMP-dependent protein kinase 1	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of platelet aggregation	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferation	cGMP-dependent protein kinase 1	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell migration	cGMP-dependent protein kinase 1	Homo sapiens (human)
regulation of testosterone biosynthetic process	cGMP-dependent protein kinase 1	Homo sapiens (human)
protein kinase A signaling	cGMP-dependent protein kinase 1	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
tachykinin receptor activity	Substance-P receptor	Homo sapiens (human)
protein binding	Substance-P receptor	Homo sapiens (human)
substance P receptor activity	Substance-P receptor	Homo sapiens (human)
protein binding	Neuromedin-K receptor	Homo sapiens (human)
tachykinin receptor activity	Neuromedin-K receptor	Homo sapiens (human)
protein kinase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
cGMP-dependent protein kinase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
calcium channel regulator activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
protein binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
ATP binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
cGMP binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
identical protein binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
mitogen-activated protein kinase p38 binding	cGMP-dependent protein kinase 1	Homo sapiens (human)
protein serine kinase activity	cGMP-dependent protein kinase 1	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
plasma membrane	Substance-P receptor	Homo sapiens (human)
cell surface	Substance-P receptor	Homo sapiens (human)
dendrite	Substance-P receptor	Homo sapiens (human)
sperm flagellum	Substance-P receptor	Homo sapiens (human)
cell body	Substance-P receptor	Homo sapiens (human)
sperm head	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
plasma membrane	Substance-P receptor	Homo sapiens (human)
sperm midpiece	Substance-P receptor	Homo sapiens (human)
plasma membrane	Neuromedin-K receptor	Homo sapiens (human)
dendrite membrane	Neuromedin-K receptor	Homo sapiens (human)
neuronal cell body membrane	Neuromedin-K receptor	Homo sapiens (human)
sperm midpiece	Neuromedin-K receptor	Homo sapiens (human)
plasma membrane	Neuromedin-K receptor	Homo sapiens (human)
sperm midpiece	Neuromedin-K receptor	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
acrosomal vesicle	cGMP-dependent protein kinase 1	Homo sapiens (human)
nucleoplasm	cGMP-dependent protein kinase 1	Homo sapiens (human)
cytoplasm	cGMP-dependent protein kinase 1	Homo sapiens (human)
Golgi apparatus	cGMP-dependent protein kinase 1	Homo sapiens (human)
cytosol	cGMP-dependent protein kinase 1	Homo sapiens (human)
plasma membrane	cGMP-dependent protein kinase 1	Homo sapiens (human)
sarcolemma	cGMP-dependent protein kinase 1	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID715672	Binding affinity to human NK1 receptor assessed as dissociation half life	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID222272	Dose (ID50) for inhibition of SP-mediated vascular leakage was determined after intravenous administration followed by resiniferatoxin (RTX) challenge 1 hour before	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID25716	Area under curve was determined after intravenous administration of compound as Bis(N-methyl-D-glucamine) salt in rat at a dose 1 mg/kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72683	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (apomorphine) challenge at 0.25 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26988	concentration in plasma after incubation in human blood after 120 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID271466	Displacement of [125I]SP from human cloned NK1 receptor expressed in CHO cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
AID72562	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (morphine) challenge at 0.5 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26973	concentration in human hepatic cytosolic subcellular fractions after 30 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26991	concentration in plasma after incubation in human blood after 60 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID270528	Inhibition of foot tapping in iv dosed gerbil after 4 hrs by CNS assay	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID26990	concentration in plasma after incubation in human blood after 30 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID77134	Inhibition of resiniferatoxin-induced systemic vascular leakage in guinea pig (SYVAL) upon oral administration at 24 hr r	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID25482	Area under curve (AUC) was determined after intravenous administration in dog at a dose of 0.5 mg/kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26993	concentration in plasma after incubation in rat after 120 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID25483	Area under curve (AUC) was determined after intravenous administration in dog at a dose of 2 mg/kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72687	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (apomorphine) challenge at 0.25 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID26986	concentration in plasma after incubation in dog after 60 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26972	concentration in human hepatic cytosolic subcellular fractions after 15 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72559	compound was tested for antiemetic action in ferret at 0.3 mg/kg after intravenous administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID342286	Inhibition of NK1 receptor	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The many roles for fluorine in medicinal chemistry.
AID75086	Inhibition of GR-73632-induced Gerbil foot tapping after immediate pretreatment iv	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID270527	Solubility in potassium hydrogen buffer at pH 5	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID270514	Displacement of [125I]SP from human cloned NK1 receptor expressed in CHO cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID271473	Solubility in potassium hydrogen phosphate buffer at pH 5	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
AID26984	concentration in plasma after incubation in dog after 15 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID76983	Inhibition of resiniferatoxin-induced systemic vascular leakage in guinea pig (SYVAL) upon oral administration at 1 hr	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID342287	Inhibition of resiniferatoxin-induced systemic vascular leakage in po dosed guinea pig emesis model after 24 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The many roles for fluorine in medicinal chemistry.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID25488	Area under curve (AUC) was determined after intravenous administration of compound as Bis(N-methyl-D-glucamine) salt in dog at a dose of 32 mg/Kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26975	concentration in human hepatic microsomal subcellular fractions after 0 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID208406	Displacement of [125I]-labeled SP from the human Tachykinin receptor 1 expressed in CHO cells	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1220560	Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1817621	Selectivity index, ratio of IC50 for human MRC5 to IC50 for human A549	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID25485	Area under curve (AUC) was determined after intravenous administration in rat at a dose of 5 mg/kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID270515	Solubility in acetate buffer at pH 5	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID1220558	Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID26974	concentration in human hepatic cytosolic subcellular fractions after 60 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72568	Dose-dependent reduction in cisplatin-induced vomiting in ferrets at 0.1 mg/kg iv dose	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220556	Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID715707	Displacement of radioligand [3H]SP from human NK1 F264Y6.51 mutant expressed in HEK293 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID26976	concentration in human hepatic microsomal subcellular fractions after 120 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID270517	Inhibition of SP-elicited plasma extravasation in esophagus of orally dosed guinea pig after 1 hr by SYVAL assay	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID72570	Dose-dependent reduction in cisplatin-induced vomiting in ferrets at 1.0 mg/kg iv dose	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID1817619	Anti-cancer activity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID222274	Dose (ID50) for inhibition of SP-mediated vascular leakage was determined after oral administration followed by resiniferatoxin (RTX) challenge 1 hour	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID222273	Dose (ID50) for inhibition of SP-mediated vascular leakage was determined after intravenous administration followed by resiniferatoxin (RTX) challenge 24 hour before	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26971	concentration in human hepatic cytosolic subcellular fractions after 120 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72686	compound was tested for antiemetic action in ferret at 0.3 mg/kg after intravenous administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID72689	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (morphine) challenge at 0.5 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID25487	Area under curve (AUC) was determined after intravenous administration of compound as Bis(N-methyl-D-glucamine) salt in dog at a dose of 2 mg/Kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72556	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (apomorphine) challenge at 0.25 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID26996	concentration in plasma after incubation in rat after 60 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID715705	Displacement of radioligand [3H]osanetant at human NK3 Y315F6.51 mutant expressed in HEK293 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID1220554	Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID270525	Solubility at pH 8.2	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID72558	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (morphine) challenge at 0.5 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID26970	concentration in human hepatic cytosolic subcellular fractions after 0 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26994	concentration in plasma after incubation in rat after 15 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID75084	Inhibition of GR 73632-induced foot tapping in gerbils upon intravenous administration of compound after 4 hr	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID208440	compounds were evaluated for inhibitory activity against human Tachykinin receptor 1	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID715902	Competitive inhibition of human NK1 F264Y6.51 mutant expressed in HEK293 cells assessed as decrease in SP1-induced [3H]IP accumulation after 20 mins	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID1817620	Anti-cancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID72684	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID72682	compound was tested for antiemetic action in ferret at 0.3 mg/kg after intravenous administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID715901	Noncompetitive inhibition of wild type human NK1 receptor expressed in HEK293 cells assessed as decrease in SP1-induced [3H]IP accumulation after 20 mins	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID72688	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID301059	Displacement of [125I]SP from human NK1 receptor expressed in CHO cells	2007	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19	Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.
AID301062	Inhibition of human CYP3A4	2007	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19	Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.
AID715704	Selectivity ratio of Ki for wild type human NK3 receptor expressed in HEK293 cells to Ki for human NK3 Y315F6.51 mutant expressed in HEK293 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID25717	Area under curve was determined after intravenous administration of compound as Bis(N-methyl-D-glucamine) salt in rat at a dose 8 mg/kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID1817661	Anti-cancer activity against human A549 cells incubated for 96 hrs by Resazurin assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID72207	inhibitory dose was determined after intravenous administration of the compound.	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID25489	Area under curve (AUC) was determined after intravenous administration of compound as Bis(N-methyl-D-glucamine) salt in rat at a dose 25 mg/Kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID25486	Area under curve (AUC) was determined after intravenous administration of compound as Bis(N-methyl-D-glucamine) salt in dog at a dose of 0.5 mg/Kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72561	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID75085	Inhibition of GR-73632-induced Gerbil foot tapping after 24 hr pretreatment iv	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID1220559	Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID342288	Inhibition of GR-73632-induced foot-tapping in iv dosed gerbils after 24 hrs	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The many roles for fluorine in medicinal chemistry.
AID72557	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID26978	concentration in human hepatic microsomal subcellular fractions after 30 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID72569	Dose-dependent reduction in cisplatin-induced vomiting in ferrets at 0.3 mg/kg iv dose	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220555	Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1237291	Displacement of [125I]-substance P from gerbil NK1 receptor expressed in HEK293 cell membranes incubated for 30 mins by liquid scintillation counting method	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitors.
AID1817660	Antagonist activity at NK1R (unknown origin) assessed as decreased IP1 levels in presence of endogenous SP ligand preincubated for 10 mins followed by 30 min incubation with antagonist and SP by HTRF-FRET assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID72566	Dose dependent reduction in cisplatin-induced retching in ferrets at 0.3 mg/kg iv dose	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID75083	Inhibition of GR 73632-induced foot tapping in gerbils upon intravenous administration of compound after 24 hr	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72567	Dose dependent reduction in cisplatin-induced retching in ferrets at 1.0 mg/kg iv dose	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID208423	In vitro inhibition of binding of [125I]-substance P to tachykinin receptor 1	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.
AID270516	Dissociation constant, pKa of the compound	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID271470	Bioavailability in orally dosed dog	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
AID271468	Dissociation constant, pKa of the compound	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
AID26995	concentration in plasma after incubation in rat after 30 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID1064184	Binding affinity to NK1 receptor (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID72555	compound was tested for antiemetic action in ferret at 0.3 mg/kg after intravenous administration followed by emetogen (cisplatin) challenge at 10 mg/kg, iv after 3 min	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID270518	Inhibition of SP-elicited plasma extravasation in esophagus of orally dosed guinea pig after 24 hrs by SYVAL assay	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID26992	concentration in plasma after incubation in rat after 0 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72560	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (apomorphine) challenge at 0.25 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID715708	Displacement of radioligand [3H]SP from wild type human NK1 receptor expressed in HEK293 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID271469	Bioavailability in orally dosed rat	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
AID208587	Binding affinity against human Tachykinin receptor 1 expressed in CHO cells using [3H]-substance P as the radioligand	2002	Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21	Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
AID25484	Area under curve (AUC) was determined after intravenous administration in rat at a dose of 2 mg/kg	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72565	Dose dependent reduction in cisplatin-induced retching in ferrets at 0.1 mg/kg iv dose	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26989	concentration in plasma after incubation in human blood after 15 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID72685	compound was tested for antiemetic action in ferret at 3 mg/kg after peroral administration followed by emetogen (morphine) challenge at 0.5 mg/kg, sc	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID715706	Displacement of [3H]osanetant from wild type human NK3 receptor expressed in HEK293 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
AID26983	concentration in plasma after incubation in dog after 120 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID270522	Inhibition of foot tapping in iv dosed gerbil after 24 hrs by CNS assay	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID271471	Solubility in isotonic saline at pH 8.2	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26982	concentration in plasma after incubation in dog after 0 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID26987	concentration in plasma after incubation in human blood after 0 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID75082	Inhibition of GR 73632-induced foot tapping in gerbils upon intravenous administration of compound	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID26985	concentration in plasma after incubation in dog after 30 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID1817659	Antagonist activity at NK1R (unknown origin) in presence of endogenous SP ligand preincubated for 10 mins followed by 30 min incubation with antagonist and SP by HTRF-FRET assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.
AID1777610	Activation of full length PKG1alpha (unknown origin) using Glass-tide peptide substrate incubated for 120 mins followed by addition of ADP-Glo max reagent incubated for 40 mins	2021	ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8	Discovery of the First Non-cGMP Mimetic Small Molecule Activators of cGMP-Dependent Protein Kinase 1 α (PKG1α).
AID26979	concentration in human hepatic microsomal subcellular fractions after 60 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID270521	Inhibition of foot tapping in iv dosed gerbil after 5 mins by CNS assay	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
AID26977	concentration in human hepatic microsomal subcellular fractions after 15 min	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID779964	Antagonist activity at NK1 receptor (unknown origin)	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
AID1220557	Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346346	Human NK1 receptor (Tachykinin receptors)	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
AID1346346	Human NK1 receptor (Tachykinin receptors)	2000	Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6	Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (0.68)	18.7374
1990's	11 (1.49)	18.2507
2000's	174 (23.61)	29.6817
2010's	400 (54.27)	24.3611
2020's	147 (19.95)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	229 (29.78%)	5.53%
Reviews	115 (14.95%)	6.00%
Case Studies	33 (4.29%)	4.05%
Observational	15 (1.95%)	0.25%
Other	377 (49.02%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (197)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetoge[NCT00337727]	Phase 3	848 participants (Actual)	Interventional	2007-01-01	Completed
Randomized, Placebo-controlled Trial of Olanzapine Versus Aprepitant Plus Ondansetron and Dexamethasone as Antiemetic Prophylaxis in Patients Receiving High Emetic Chemotherapy[NCT03876938]	Phase 3	147 participants (Anticipated)	Interventional	2019-03-01	Recruiting
A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals[NCT01300988]	Phase 1	18 participants (Actual)	Interventional	2010-12-31	Completed
Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy[NCT01344304]		413 participants (Actual)	Interventional	2011-04-30	Completed
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial[NCT03578081]	Phase 3	690 participants (Actual)	Interventional	2018-10-15	Completed
A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination With Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-containing Regimen Which Includes 5-FU.[NCT02550119]		19 participants (Actual)	Interventional	2006-04-19	Terminated(stopped due to Insufficient accrual)
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy[NCT03435003]	Phase 4	104 participants (Actual)	Interventional	2017-08-28	Completed
A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants Receiving Emetogenic Chemothe[NCT04054193]	Phase 4	103 participants (Actual)	Interventional	2019-09-09	Completed
Phase II, Double-blind, Placebo-controlled, Crossover Study Evaluating a 5HT3 Antagonist Plus Dexamethasone With or Without Fosaprepitant in Patients With Advanced NSCLC Receiving Carboplatin Based Chemotherapy[NCT02407600]	Phase 2	150 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia[NCT03197064]	Phase 4	11 participants (Actual)	Interventional	2018-01-01	Completed
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs[NCT05230654]		120 participants (Anticipated)	Interventional	2022-02-01	Not yet recruiting
Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery[NCT04853147]	Phase 3	1,154 participants (Actual)	Interventional	2021-04-27	Completed
Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers[NCT03889366]	Phase 1	12 participants (Actual)	Interventional	2019-03-20	Completed
Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries[NCT02525848]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2015-08-31	Completed
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19[NCT04470622]	Phase 2	27 participants (Actual)	Interventional	2020-07-20	Terminated(stopped due to Study was terminated early by Heron, and was not terminated for safety reasons.)
Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting: a Phase III, Double-blind, Randomized, Placebo-controlled Trial in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting[NCT01088022]	Phase 3	120 participants (Anticipated)	Interventional	2010-04-30	Not yet recruiting
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial[NCT05841849]	Phase 4	1,028 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)[NCT04606264]	Phase 3	2,500 participants (Anticipated)	Interventional	2023-05-15	Recruiting
Aprepitant vs. Placebo for the Prevention of Postoperative Nausea and Vomiting: a Randomized, Double-blind Study in Patients Undergoing Laparoscopic Cholecystectomy[NCT01020903]		200 participants (Actual)	Interventional	2009-11-30	Completed
An Open Label Phase II Study of Aprepitant for Multi-day Moderately-high to Highly Emetogenic Chemotherapy Regimens[NCT00711555]	Phase 2	22 participants (Actual)	Interventional	2005-11-30	Completed
Safety and Efficacy of Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy[NCT02445872]	Phase 2	80 participants (Anticipated)	Interventional	2015-12-31	Not yet recruiting
Evaluation of Palonosetron and Palonosetron/Aprepitant in Post Operative Nausea and Vomiting Incidence in Oncological Patients[NCT02431286]	Phase 4	90 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Phase II Randomized Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis[NCT03478605]	Phase 2	130 participants (Anticipated)	Interventional	2018-05-25	Recruiting
A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Subjects Receiving E[NCT02519842]	Phase 3	75 participants (Actual)	Interventional	2015-09-14	Terminated(stopped due to Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings)
Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy[NCT02205164]	Phase 2	134 participants (Anticipated)	Interventional	2011-10-31	Recruiting
The Optimization of Antiemetic Regimen for Chemoradiotherapy-induced Nausea and Vomiting (C-RINV) in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCCs): A Prospective Phase Ⅱ Trial[NCT05202275]	Phase 2	43 participants (Anticipated)	Interventional	2020-12-01	Recruiting
The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Thoracicsurgery Patients: A Single-center, Randomized, Double-Blinded Clinical Study[NCT05881486]		234 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
See Detailed Description[NCT00169572]	Phase 2	492 participants	Interventional	2005-02-28	Completed
A Phase IB, Open Label Study to Examine the Safety, Pharmacokinetic Characteristics and Anti-Inflammatory Effects of the NK-1R Antagonist, Aprepitant, In HIV-Infected Subjects Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir[NCT02154360]	Phase 1	12 participants (Actual)	Interventional	2014-05-31	Completed
A Prospective, Open-label, Single-arm Study for Efficacy and Safety of Three-drug Antiemetic Regimen to Prevent the Emesis During Radiotherapy With Concurrent Chemoradiotherapy in Locally Advanced HNSCC[NCT03572829]	Phase 2	44 participants (Actual)	Interventional	2018-03-01	Completed
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers[NCT03245918]	Phase 1	17 participants (Actual)	Interventional	2017-08-10	Completed
A Randomized Controlled Study to Compare (EMEND®)to Standard Treatment as Prevention for Delayed Chemotherapy-induced Nausea and Vomiting (CINV) After Myeloablative Therapy for Patients Undergoing Autologous Stem Cell Transplantation.[NCT01101529]	Phase 2	90 participants (Anticipated)	Interventional	2010-05-31	Completed
A Comparison of the Combination of Aprepitant and Dexamethasone Versus the Combination of Ondansetron and Dexamethasone for the Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Craniotomy[NCT00734929]	Phase 4	115 participants (Actual)	Interventional	2007-09-30	Completed
Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin[NCT03237611]	Phase 2	15 participants (Actual)	Interventional	2018-10-30	Terminated(stopped due to Expired IRB approval on 2/11/21)
Medications Development for the Treatment of Cannabis Related Disorders[NCT01204723]	Phase 1	63 participants (Actual)	Interventional	2009-08-31	Completed
Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics[NCT00719173]	Phase 1	19 participants (Actual)	Interventional	2005-08-31	Completed
Prevention of Nausea and Vomitting Associated With Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used With Highly Emetogenic Preparative Regimens[NCT00781768]	Phase 4	181 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects[NCT00990821]	Phase 1	188 participants (Actual)	Interventional	2005-01-31	Completed
A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy[NCT00818259]	Phase 1	92 participants (Actual)	Interventional	2009-02-05	Terminated(stopped due to Study terminated early prior to completing targeted enrollment of participants <6 months of age due to recruitment challenges.)
Clinical on the Safety and Effectiveness of Fosaprepitant Dimeglumine for Injection in the Prevention of Nausea and Vomiting Caused by Tumor Chemotherapy Drugs.[NCT05755659]		3,000 participants (Anticipated)	Interventional	2022-07-15	Recruiting
Aprepitant to Mitigate Opioids' Cognitive Side Effects[NCT02226601]		50 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Comparative Trial Ondansetron Alone Versus Combination of Ondansetron Plus Aprepitant for Prevention of Nausea and Vomiting With Hematologic Malignancies Receiving Regimens Containing High-dose Cytarabine[NCT00954941]	Phase 2	100 participants (Actual)	Interventional	2009-11-30	Completed
Randomized Phase 3 Study of Aprepitant Versus Placebo in Chinese Advanced Non-small Cell Lung Cancer Who Received Highly Emetogenic Chemotherapy[NCT02161991]	Phase 3	244 participants (Actual)	Interventional	2014-02-01	Completed
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Ped[NCT01362530]	Phase 3	307 participants (Actual)	Interventional	2011-09-13	Completed
An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects[NCT02058277]	Phase 1	20 participants (Actual)	Interventional	2014-05-31	Completed
A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation[NCT02576327]	Phase 4	130 participants (Anticipated)	Interventional	2015-10-31	Active, not recruiting
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin.[NCT01074697]	Phase 3	246 participants (Actual)	Interventional	2010-04-30	Completed
A Phase 2 Open-Label Study of HTX-011 Via Individualized Dosing Administration for Postoperative Analgesia Following Unilateral Simple Bunionectomy[NCT03718039]	Phase 2	78 participants (Actual)	Interventional	2018-10-24	Completed
Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients With Non-Hodgkin's Lymphoma[NCT00651755]		23 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Double-blind, Placebo-controlled Clinical Study on Prevention and Treatment of CINV Induced by TC Regimen in Gynecological Malignant Tumors[NCT06007586]	Phase 4	138 participants (Anticipated)	Interventional	2024-02-10	Not yet recruiting
Comparison of Dual Therapy of Dexamethasone and Palonosetron and Triple Therapy of Dexamethasone, Palonosetron, Fosaprepitant for Postoperative Nausea and Vomiting Prevention: A Randomized Controlled Trial[NCT05773950]		144 participants (Anticipated)	Interventional	2023-08-18	Enrolling by invitation
A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement[NCT02336750]	Phase 3	212 participants (Actual)	Interventional	2014-12-31	Completed
Prevention of Postoperative Nausea and Vomiting in a Gynecologic Surgery Population: A Randomized Placebo Controlled Trial of Aprepitant NK-1-receptor Antagonist[NCT00888329]	Phase 4	256 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to Slow accrual.)
A Randomized and Placebo-Controlled Evaluation of Aprepitant for Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients[NCT00956215]		125 participants (Actual)	Interventional	2010-05-31	Completed
MK0869 and MK0517 Time-on-Target PET Study[NCT01111851]	Phase 1	16 participants (Actual)	Interventional	2010-04-30	Completed
Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy[NCT02532634]	Phase 4	292 participants (Actual)	Interventional	2015-08-19	Completed
A Multi-center, 2-Part Study to Evaluate the Pharmacokinetics Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery[NCT00819039]	Phase 1	98 participants (Actual)	Interventional	2009-01-26	Completed
Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study[NCT00600353]	Phase 2	20 participants (Actual)	Interventional	2007-10-31	Completed
A Prospective, Open Label, Non-comparative Trial to Determine the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients[NCT01298193]	Phase 4	212 participants (Actual)	Interventional	2011-05-31	Completed
A Comparison of Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients[NCT00738621]	Phase 4	100 participants (Actual)	Interventional	2008-07-31	Completed
Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287]	Phase 3	429 participants (Actual)	Interventional	2017-09-23	Completed
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents[NCT01249001]	Phase 2	4 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to lack of eligible participants to enrol)
A Phase III, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Safety, Tolerability and Efficacy of MK0869/Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated Wit[NCT00952341]	Phase 3	421 participants (Actual)	Interventional	2009-08-25	Completed
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen[NCT00572572]	Phase 3	69 participants (Actual)	Interventional	2007-12-31	Completed
A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects[NCT00945321]	Phase 1	42 participants (Actual)	Interventional	2009-02-28	Completed
A Phase II Study to Evaluate the Efficacy and Tolerability of Ramosetron, Aprepitant and Dexamethasone (RAD) in Preventing Cisplatin-induced Nausea and Vomiting in Chemotherapy-naïve Patients With Solid Cancer[NCT01046461]	Phase 2	41 participants (Actual)	Interventional	2010-01-31	Active, not recruiting
A Randomized, Double-Blind Comparison of Oral Aprepitant and Lower Dose Dexamethasone vs Aprepitant Alone for Preventing Postoperative Nausea and Vomiting After Elective Laparoscopic Surgeries[NCT00835965]		50 participants (Anticipated)	Interventional	2009-02-28	Not yet recruiting
Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting After Laparoscopic Sleeve Surgery: a Randomized Controlled Trial[NCT04013386]	Phase 4	90 participants (Actual)	Interventional	2019-07-15	Completed
A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Indu[NCT00619359]	Phase 3	2,322 participants (Actual)	Interventional	2008-02-29	Completed
Developing Individualized Strategies to Prevent Nausea and Vomiting[NCT01393288]		0 participants (Actual)	Interventional	2013-11-30	Withdrawn
A Study to Evaluate the Anti-emetic Effect of Aprepitant Versus Placebo as an Add-on Therapy in Children and Adolescent Receiving Chemotherapy: A Randomized, Doubly Blinded Controlled Trial[NCT01402024]	Phase 3	96 participants (Actual)	Interventional	2011-08-31	Completed
Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study[NCT00869973]	Phase 3	580 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to We terminated the study after enrolling 580/900 patients due to a slow accrual)
FORESIGHT: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy: a Randomised Controlled Trial Against Aprepitant in Triple Therapy[NCT04075955]	Phase 3	30 participants (Actual)	Interventional	2019-04-29	Completed
A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation[NCT00895245]	Phase 2	6 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to Study stopped due to lack of efficacy in first 6 patients)
Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition[NCT02130687]		106 participants (Actual)	Interventional	2014-06-30	Completed
Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen[NCT00970905]	Phase 2	52 participants (Actual)	Interventional	2009-10-31	Completed
Pilot Study of the Action of the Substance P Antagonist Aprepitant on Aldosterone and Cortisol Secretion in Healthy Volunteers.[NCT00977223]	Phase 4	20 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety and Tolerability of IV MK0517 for the Prevention of Postoperative Nausea and Vomiting (PONV)[NCT00231777]	Phase 3	216 participants (Actual)	Interventional	2005-07-31	Completed
Pilot Study Exploring the Efficacy of Prolonged Emend to Reduce Nausea and Vomiting During Treatment in a Phase II Study (NYU 03-67) of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer[NCT01017809]		0 participants (Actual)	Interventional	2010-12-31	Withdrawn(stopped due to NYU 03-67 reached accrual prior to this study opening.)
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation[NCT00293384]		40 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study[NCT01913990]	Phase 4	323 participants (Anticipated)	Interventional	2011-09-30	Active, not recruiting
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial[NCT01149369]	Phase 2	126 participants (Actual)	Interventional	2013-04-30	Completed
THE EFFECT OF THE COMBINATION OF DEXAMETHASONE WITH ONDANSETRON VERSUS DEXAMETHASONE WITH APREPITANT TO PREVENT POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LAPAROSCOPIC SURGERY[NCT02021851]	Phase 4	67 participants (Actual)	Interventional	2011-07-31	Completed
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Stu[NCT04536558]	Phase 3	352 participants (Anticipated)	Interventional	2020-10-01	Not yet recruiting
Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients[NCT01683552]	Phase 2	45 participants (Actual)	Interventional	2010-09-30	Completed
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade：an Randomized Clinical Trial[NCT06080880]		98 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response[NCT01649258]	Phase 1	29 participants (Actual)	Interventional	2012-09-04	Terminated(stopped due to Lack of Efficacy)
Modulation of Opiate Reward by NK1 Antagonism: A Laboratory-Based Proof of Concept Study[NCT00726960]	Phase 1	60 participants (Anticipated)	Interventional	2008-01-31	Active, not recruiting
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial[NCT00869310]	Phase 3	303 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to we terminated the study before enrolling 303/560 due to a slow accrual)
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020]	Phase 2	138 participants (Actual)	Interventional	2015-12-31	Completed
Comparison of Aprepitant PO and Ondansetron IV for Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Orthognathic Surgery and General Anesthesia.[NCT00699894]		0 participants (Actual)	Interventional	2008-06-30	Withdrawn(stopped due to Logistical difficulties running the study)
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma[NCT02770378]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2016-11-30	Completed
Re-examination Study For General Drug Use to Assess the Safety and Efficacy Profile of EMEND in Usual Practice[NCT01074255]		3,546 participants (Actual)	Observational	2007-04-30	Completed
Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin[NCT02811055]	Phase 2	20 participants (Anticipated)	Interventional	2017-07-13	Recruiting
Compared With Fosaprepitant Dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of HR20013 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy[NCT05509634]	Phase 3	754 participants (Actual)	Interventional	2022-09-21	Completed
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies[NCT00871910]	Phase 1	81 participants (Actual)	Interventional	2006-10-11	Completed
Steroid-free Regimen With Aprepitant in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Receiving FOLFOX Chemotherapy: a Randomized Phase 3 Trial[NCT02909478]	Phase 3	315 participants (Actual)	Interventional	2017-09-01	Completed
A Pilot Study of Aprepitant Versus Ondansetron for the Treatment of Opioid Induced Nausea and Vomiting[NCT00499668]		0 participants (Actual)	Interventional	2007-08-31	Withdrawn(stopped due to slow accrual)
The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastric Sleeve Surgery[NCT05772676]	Phase 4	400 participants (Actual)	Interventional	2022-12-01	Active, not recruiting
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients：a Randomized Phase 3 Trial[NCT02933099]	Phase 3	300 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3[NCT04649229]	Phase 4	80 participants (Anticipated)	Interventional	2021-05-27	Recruiting
Pharmacological Treatment of Cannabis Withdrawal and Dependence[NCT01611948]	Phase 2	70 participants (Actual)	Interventional	2011-05-31	Completed
COMPARATIVE STUDY BETWEEN PALONOSETRON AND FOSAPREPITANT IN THE PROFILAXIA OF POSTOPERATIVE NAUSEA AND VOMITING IN WOMEN SUBMITTED TO VIDEOLAPAROSCOPIC COLECISTECTOMIES[NCT03586817]	Phase 4	100 participants (Anticipated)	Interventional	2019-03-02	Recruiting
Comparison of Aprepitant vs. Gabapentin in the Prevention of Delayed Nausea and Vomiting[NCT00250744]	Phase 2	200 participants (Actual)	Interventional	2004-12-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated W[NCT00080444]	Phase 3	50 participants (Actual)	Interventional	2004-04-30	Completed
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety, Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vo[NCT00090207]	Phase 4	477 participants (Actual)	Interventional	2004-01-13	Completed
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomitin[NCT00090246]	Phase 3	922 participants (Actual)	Interventional	2004-05-13	Completed
A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation[NCT00314743]	Early Phase 1	48 participants (Actual)	Interventional	2005-10-31	Completed
Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With [NCT00092196]	Phase 3	820 participants (Actual)	Interventional	2002-12-01	Completed
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients：A Superiority Design, Phase III Randomized Trial[NCT04873284]		120 participants (Anticipated)	Interventional	2021-05-01	Not yet recruiting
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomitin[NCT00090155]	Phase 3	805 participants (Actual)	Interventional	2003-09-26	Completed
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Che[NCT00092183]	Phase 4	866 participants (Actual)	Interventional	2002-10-10	Completed
A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Bleomycin -Etoposide - Cisplatin (BEP) Treatment of Patients With Testis Carcinoma (A-BEP)[NCT00429754]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to change of study population and chemotherapeutic regimen)
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial[NCT00475085]	Phase 3	1,021 participants (Actual)	Interventional	2006-12-31	Completed
The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting[NCT01897337]	Phase 4	125 participants (Actual)	Interventional	2012-06-30	Completed
A Randomized, Double-blind Comparison of Oral Aprepitant Alone vs Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting[NCT00717054]		115 participants (Actual)	Interventional	2008-02-29	Completed
A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Cisplatin - Etoposide (CE) Treatment of Patients With Metastatic Lung Carcinoma (ACE).[NCT00588835]	Phase 4	20 participants (Anticipated)	Interventional	2008-03-31	Terminated
New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone[NCT00999544]		9 participants (Actual)	Interventional	2009-10-31	Completed
A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals[NCT00428519]	Phase 1	30 participants (Actual)	Interventional	2007-01-31	Completed
Clinical Laboratory Evaluations of Aprepitant for the Treatment of Opioid Dependence: Inpatient Test[NCT01527994]	Phase 1	64 participants (Actual)	Interventional	2012-01-31	Completed
To Assess the Efficacy and Safety of Ramosetron, Aprepitant and Dexamethasone Therapy vs Ondansetron, Aprepitant and Dexamethasone Therapy for Preventing of Nausea and Vomiting in Highly Emetogenic Chemotherapy (ROAD Study)[NCT01536691]	Phase 3	338 participants (Anticipated)	Interventional	2011-06-30	Recruiting
A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder[NCT00048607]	Phase 3	600 participants (Actual)	Interventional	2002-07-30	Completed
A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder[NCT00034944]	Phase 3	495 participants (Actual)	Interventional	2002-01-24	Completed
A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder[NCT00034983]	Phase 3	900 participants (Actual)	Interventional	2001-10-29	Completed
A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder[NCT00035295]	Phase 3	584 participants (Actual)	Interventional	2001-11-08	Completed
A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features[NCT00035009]	Phase 3	468 participants (Actual)	Interventional	2001-09-20	Completed
A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients With Major Depressive Disorder[NCT00035048]	Phase 3	540 participants (Actual)	Interventional	2001-11-21	Completed
A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder[NCT00035282]	Phase 3	450 participants (Actual)	Interventional	2001-09-30	Completed
ONO-7436 Phase II Study - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7436 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Japan[NCT00212602]	Phase 2	420 participants	Interventional	2005-08-31	Completed
A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder[NCT00042029]	Phase 3	324 participants (Actual)	Interventional	2002-06-18	Completed
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting[NCT01474915]	Phase 4	122 participants (Actual)	Interventional	2007-06-30	Completed
A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Patients With Major Depressive Disorder[NCT00048594]	Phase 3	800 participants (Actual)	Interventional	2002-01-03	Completed
A Randomized, Double-blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting[NCT00659737]		115 participants (Actual)	Interventional	2008-04-30	Completed
ApRepitant in Combination With Granisetron and Dexamethasone versUs Granisetron and dexamEthasone for the Prevention of Vomiting in Patients With HAIC Therapy for Hepatocellular Carcinoma: a Randomized Controlled Study (ARGUE)[NCT05711823]	Phase 3	300 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma[NCT02780609]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2017-07-20	Completed
Influence of Antipruritics on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin[NCT04399148]		13 participants (Actual)	Interventional	2019-06-11	Completed
A Randomized, Double-Blind, Prospective Trial of Oral Administration of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis[NCT00736073]		73 participants (Actual)	Interventional	2007-08-31	Completed
Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.[NCT03808805]	Phase 3	80 participants (Anticipated)	Interventional	2019-04-16	Recruiting
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexameth[NCT02106494]	Phase 3	942 participants (Actual)	Interventional	2014-03-31	Completed
Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC).[NCT01640340]		40 participants (Actual)	Interventional	2011-01-31	Completed
Efficacy of Pre-operative Aprepitant Plus Ondansetron vs Ondansetron Plus Placebo in Patients at Moderate-to-High Risk Post-operative Nausea (PONV) Undergoing Ambulatory Plastic Surgery[NCT00659945]	Phase 4	150 participants (Actual)	Interventional	2008-06-30	Completed
AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nause[NCT00415103]	Phase 4	196 participants (Anticipated)	Interventional	2006-11-30	Completed
Granisetron Transdermal Delivery System Versus Palonosetron in the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting: a Phase 3 Non-inferiority Randomized Trial[NCT04912271]	Phase 3	140 participants (Anticipated)	Interventional	2021-06-10	Not yet recruiting
"Olanzapine for Prevention of Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC): An Investigator Initiated, Randomized, Open-label Trial (PRaCTiCE Trial: PRevention of ChemoTherapy Induced Emesis in Children)"[NCT03219710]	Phase 3	240 participants (Actual)	Interventional	2017-07-01	Completed
Efficacy of Aprepitant (Emend®) in Children Receiving Highly Emetogenic Chemotherapy[NCT01661335]	Phase 3	19 participants (Actual)	Interventional	2012-06-01	Completed
EMEND® IV In Salvage Treatment of Chemotherapy-Induced Vomiting[NCT01405924]	Phase 2	111 participants (Actual)	Interventional	2011-10-25	Terminated(stopped due to Low enrollment)
A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP.[NCT01843868]		130 participants (Anticipated)	Interventional	2013-05-31	Not yet recruiting
A Study to Evaluate the Efficacy of Anti-emetic Drug Aprepitant Upon the Combination Chemotherapy of Nedaplatin and Docetaxel for Non-small Cell Lung Cancer[NCT02364804]		10 participants (Anticipated)	Observational	2012-04-30	Completed
Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant[NCT02597907]		88 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Pati[NCT01450826]	Phase 2	136 participants (Actual)	Interventional	2014-06-24	Completed
Topical Aprepitant in Prurigo Patients An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo[NCT01963793]	Phase 2	20 participants (Actual)	Interventional	2013-10-31	Completed
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome[NCT01625455]	Phase 4	7 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Difficulty recruiting.)
Retrospective Comparison of the Effects of Granisetron and Aprepitant in the Prevention of Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery[NCT05632224]	Phase 4	60 participants (Anticipated)	Interventional	2022-11-24	Not yet recruiting
Weekly Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma: a Prospective Pilot Study[NCT04636632]	Phase 1	100 participants (Actual)	Interventional	2020-11-24	Completed
[NCT01440673]		150 participants (Actual)	Interventional	2010-03-31	Completed
Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting[NCT01031953]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to Drug contract timelines and inadequate enrollment)
Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial[NCT02979548]	Phase 3	116 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Fosaprepitant Combined With Tropisetron Plus Dexamethasone in Preventing Nausea and Emesis During Fractionated Radiotherapy With Weekly Cisplatin Chemotherapy in Cervical Cancer and Nasopharyngeal Cancer[NCT05564286]	Phase 3	206 participants (Anticipated)	Interventional	2021-07-01	Recruiting
A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer[NCT01432015]	Phase 4	20 participants (Actual)	Interventional	2011-09-30	Completed
Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery: a Prospective, Randomised, Placebo-controlled, Triple-blind, Single Centre Trial.[NCT05189756]	Phase 4	224 participants (Anticipated)	Interventional	2022-03-17	Recruiting
Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving[NCT01176591]	Phase 2	13 participants (Actual)	Interventional	2010-09-30	Completed
Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury[NCT03035838]	Early Phase 1	0 participants (Actual)	Interventional	2021-11-30	Withdrawn(stopped due to Alternate study commenced using different drug)
Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen[NCT01490060]		47 participants (Actual)	Interventional	2012-05-31	Completed
A Single-Center, Placebo-Controlled, Double-Blind Study to Evaluate the Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying in Healthy Volunteers[NCT02989467]	Phase 1	27 participants (Actual)	Interventional	2017-01-27	Completed
Differentiating the Effects of Substance P and Beta-endorphin in the Perception of Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease (COPD)[NCT01854177]		10 participants (Actual)	Interventional	2013-07-31	Completed
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence[NCT02210195]	Phase 2	20 participants (Actual)	Interventional	2014-09-04	Completed
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis[NCT02625181]		27,034 participants (Actual)	Interventional	2016-07-31	Completed
Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy[NCT01275664]		4 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Study terminated due to no patient population available)
A Phase II Open Label Study of Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy[NCT01334086]	Phase 2	41 participants (Actual)	Interventional	2011-09-30	Completed
A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R[NCT01636947]	Phase 4	494 participants (Actual)	Interventional	2012-12-12	Completed
Efficacy and Safety Addition of Low Dose Olanzapine to the Standard Prophylaxis of Nausea and Vomiting Induced by Highly-emetogenic Chemotherapy in Children and Adolescents (OZONE-V)[NCT05346731]	Phase 3	210 participants (Anticipated)	Interventional	2022-04-01	Recruiting
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial[NCT02116530]	Phase 3	401 participants (Actual)	Interventional	2014-08-31	Completed
Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline/Cyclophosphamide-containing Chemotherapy[NCT05242874]	Phase 3	403 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Phase 2B Double Blind Placebo Controlled Crossover Study Evaluating the Efficacy of IV Fosaprepitant for Chemo Induced N/V With High Dose Interleukin 2 for Metastatic Melanoma and Metastatic Renal Cell Carcinoma[NCT01874119]	Phase 2	13 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to Enrollment issues)
Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial[NCT03674294]	Phase 3	248 participants (Actual)	Interventional	2015-08-04	Completed
A Feasibility Study to Discern the Tolerability of 5-FU/Gemcitabine Based Chemotherapy Concurrent With Upper Abdominal Radiation and the Utility of Aprepitant/5HT-3 Antagonist (EMEND) for the Prevention of ChemoRadiation-Induced Nausea and Vomiting (CRINV[NCT01534637]	Phase 2	22 participants (Actual)	Interventional	2006-08-31	Completed
A Pilot Study of Aprepitant vs. Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplatation(HCT)[NCT00248547]		40 participants (Actual)	Interventional	2004-05-31	Completed
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)[NCT02347878]	Phase 4	85 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention [NCT01594749]	Phase 3	1,015 participants (Actual)	Interventional	2012-09-24	Completed
Effect of the Association of Neurokinin-1 Receptor Antagonist Aprepitant to Dexamethasone/Ondansetron in the Incidence of Postoperative Nausea and Vomiting in High Risk Apfel Score Patients[NCT02357693]	Phase 4	90 participants (Actual)	Interventional	2015-02-28	Completed
A Comparison Study to Determine the Increased Efficacy of Adding EMEND to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting[NCT01186029]		0 participants (Actual)	Interventional	2010-10-31	Withdrawn(stopped due to It didn't get IRB approval.)
Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study[NCT01183481]	Phase 2	19 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Study was stopped due to inadequate accrual.)
The Role of Substance P on Perception of Breathlessness[NCT01580423]		16 participants (Actual)	Interventional	2012-04-30	Completed
A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX[NCT00381862]	Phase 2	54 participants (Actual)	Interventional	2006-06-30	Completed
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153[NCT01736917]	Phase 2	65 participants (Actual)	Interventional	2013-01-31	Completed
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD[NCT00896038]	Phase 2	58 participants (Actual)	Interventional	2009-05-31	Completed
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin[NCT01012336]	Phase 2	89 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized Study to Determine the Efficacy and Tolerability of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients[NCT03079219]	Phase 3	120 participants (Actual)	Interventional	2017-03-23	Completed
Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients[NCT01504711]		30 participants (Actual)	Interventional	2012-06-30	Completed
A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy[NCT01376297]	Phase 3	413 participants (Actual)	Interventional	2011-07-31	Completed
Efficacy, Safety and Feasibility of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients With Solid Tumors Receiving Moderately and Highly Emetogenic Chemotherapy[NCT04508400]	Phase 2	108 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy[NCT01857232]	Phase 2	342 participants (Actual)	Interventional	2013-10-31	Completed
A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting[NCT01732458]	Phase 2	229 participants (Actual)	Interventional	2013-02-12	Completed
Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)[NCT02732015]	Phase 2	37 participants (Actual)	Interventional	2016-10-12	Terminated(stopped due to Terminated per PI's request)
A Pilot Study Comparing Olanzapine and Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Receiving Highly Emetogenic Chemotherapy[NCT02097823]	Phase 2	15 participants (Actual)	Interventional	2014-02-28	Completed
A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomitin[NCT01697579]	Phase 2	240 participants (Actual)	Interventional	2012-12-13	Completed
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial[NCT02484911]	Phase 3	120 participants (Actual)	Interventional	2015-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00231777 (4) [back to overview]	Number of Patients With Clinical Adverse Experiences (CAEs)
NCT00231777 (4) [back to overview]	Number of Patients With Drug-related CAEs
NCT00231777 (4) [back to overview]	Number of Patients With Laboratory Adverse Experiences (LAEs)
NCT00231777 (4) [back to overview]	Number of Patients With Serious CAEs
NCT00248547 (1) [back to overview]	Number of Emesis Free Participants During the Study Period.
NCT00293384 (4) [back to overview]	Overall Nausea Controlled
NCT00293384 (4) [back to overview]	Delayed Vomiting Controlled
NCT00293384 (4) [back to overview]	Proportion of Participants With Controlled Acute Vomiting
NCT00293384 (4) [back to overview]	Toxicity Grade 3, 4, or 5
NCT00337727 (2) [back to overview]	Number of Patients Who Reported No Vomiting
NCT00337727 (2) [back to overview]	Number of Patients Who Reported Complete Response
NCT00381862 (1) [back to overview]	Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.
NCT00475085 (1) [back to overview]	Home Record: Severity of Delayed Nausea
NCT00572572 (6) [back to overview]	Proportion of Patients With no Emesis During the Acute CINV Time Period (Cycle Days 1-5)
NCT00572572 (6) [back to overview]	Preferred Treatment Cycle
NCT00572572 (6) [back to overview]	Visual Analouge (VAS) 100mm Scale Score
NCT00572572 (6) [back to overview]	Proportion of Patients With no Emesis During the Delayed CINV Time Period (Cycle Days 6-8)
NCT00572572 (6) [back to overview]	Complete Response.
NCT00572572 (6) [back to overview]	MD Anderson Symptom Inventory Score
NCT00600353 (4) [back to overview]	Overall Emetic Response
NCT00600353 (4) [back to overview]	Overall Emetic Response: Acute
NCT00600353 (4) [back to overview]	Overall Emetic Response: Extended
NCT00600353 (4) [back to overview]	Overall Emetic Response: Delayed
NCT00619359 (3) [back to overview]	No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)
NCT00619359 (3) [back to overview]	A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).
NCT00619359 (3) [back to overview]	A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).
NCT00651755 (6) [back to overview]	Geometric Mean Area Under Curve (AUC) of Analyte, Vincristine (VC), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]	Geometric Mean Area Under Curve (AUC) of Analyte,Prednisone (PR), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]	Geometric Mean Area Under Curve (AUC) of Analyte, Prednisolone (PL), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]	Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]	Geometric Mean Area Under Curve (AUC) of Analyte, 4-hydroxy-cyclophosphamide (4-OH-CP), in Aprepitant Treatment and Control Group
NCT00651755 (6) [back to overview]	Geometric Mean Area Under Curve (AUC) of Analyte, 2-dechloro-cyclophosphamide(2-deCI-CP), in Aprepitant Treatment and Control Group
NCT00659737 (1) [back to overview]	Number of Participants With Postoperative Nausea and Vomiting
NCT00659945 (1) [back to overview]	Number of Participants Having Post-operative Emesis and Nausea.
NCT00711555 (5) [back to overview]	Complete Protection
NCT00711555 (5) [back to overview]	Complete Response (Percentage of Patients)
NCT00711555 (5) [back to overview]	no Emesis
NCT00711555 (5) [back to overview]	no Nausea
NCT00711555 (5) [back to overview]	no Significant Nausea
NCT00717054 (4) [back to overview]	Number of Participants With Nausea and Vomiting
NCT00717054 (4) [back to overview]	Number of Participants With Nausea and Vomiting in PACU
NCT00717054 (4) [back to overview]	Total Vomiting
NCT00717054 (4) [back to overview]	Need for Antiemetic Medication
NCT00734929 (12) [back to overview]	Cumulative Incidence of Emesis
NCT00734929 (12) [back to overview]	Average Nausea Score
NCT00734929 (12) [back to overview]	Incidence of Vomiting (Post OP)
NCT00734929 (12) [back to overview]	"Number of Participants Who Rated Their Satisfaction With Antiemetic Management as Very Satisfied"
NCT00734929 (12) [back to overview]	Number of Vomiting Episodes
NCT00734929 (12) [back to overview]	Incidence of Vomiting (24 Hours)
NCT00734929 (12) [back to overview]	Time to First Vomiting
NCT00734929 (12) [back to overview]	Use of Rescue Antiemetics (24 Hours)
NCT00734929 (12) [back to overview]	Use of Rescue Antiemetics (48 Hours)
NCT00734929 (12) [back to overview]	Use of Rescue Antiemetics (Post OP)
NCT00734929 (12) [back to overview]	Incidence of Nausea
NCT00734929 (12) [back to overview]	Number of Participants With a Complete Response Rate
NCT00736073 (2) [back to overview]	Number of Participants Who Were Hospitalized Within 7 Days Post-ERCP for Abdominal Pain That Did Not Meet Criteria for Acute Pancreatitis
NCT00736073 (2) [back to overview]	Number of Post-ERCP Pancreatitis Cases in Participants Who Are Administered Aprepitant and Placebo Prior to ERCP and One Day After ERCP:Assess the Total Number of Incidents of Post-ERCP Pancreatitis in Each Group (Treatment and Control).
NCT00818259 (8) [back to overview]	Number of Participants Discontinuing Study Drug Due to an AE
NCT00818259 (8) [back to overview]	Apparent Terminal Half-life (t1/2) for Aprepitant
NCT00818259 (8) [back to overview]	Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant
NCT00818259 (8) [back to overview]	Tmax for Fosaprepitant
NCT00818259 (8) [back to overview]	Cmax for Fosaprepitant
NCT00818259 (8) [back to overview]	Maximum Plasma Concentration (Cmax) for Aprepitant
NCT00818259 (8) [back to overview]	Time to Cmax (Tmax) for Aprepitant
NCT00818259 (8) [back to overview]	Number of Participants Experiencing Adverse Events (AEs)
NCT00819039 (12) [back to overview]	Number of Participants Discontinuing Study Treatment Due to AEs
NCT00819039 (12) [back to overview]	Number of Participants Experiencing Adverse Events (AEs)
NCT00819039 (12) [back to overview]	Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2
NCT00819039 (12) [back to overview]	Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2
NCT00819039 (12) [back to overview]	Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2
NCT00819039 (12) [back to overview]	Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1
NCT00819039 (12) [back to overview]	Maximum Plasma Concentration (Cmax) of Aprepitant Following a Single Oral Dose in Study Part 1
NCT00819039 (12) [back to overview]	Number of Participants With Vomiting Frequency in Study Part 2
NCT00819039 (12) [back to overview]	Plasma Concentration of Aprepitant at 24 Hours (C24 hr) Following a Single Oral Dose in Study Part 1
NCT00819039 (12) [back to overview]	Plasma Concentration of Aprepitant at 48 Hours (C48 hr) Following a Single Oral Dose in Study Part 1
NCT00819039 (12) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Aprepitant Following a Single Oral Dose in Study Part 1
NCT00819039 (12) [back to overview]	Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2
NCT00888329 (1) [back to overview]	Number of Participants With Emesis
NCT00895245 (4) [back to overview]	Rate of Complete Response to Anti-emetic Therapy in the Delayed Setting (25-120 Hours After Cisplatin Infusion)
NCT00895245 (4) [back to overview]	Proportion of Patients With a Complete Response to the Anti-emetic Medication Regimen
NCT00895245 (4) [back to overview]	Impact of Cisplatin-induced Nausea and Vomiting on Daily Life During the 5 Day Period Following Cisplatin Infusion for Multiple Cycles as Measured by the Functional Living Index-Emesis Questionnaire
NCT00895245 (4) [back to overview]	Control of Nausea for 120 Hours Following Each Cisplatin Infusion for Multiple Cycles of Therapy as Measured by the Visual Analog Scale
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	PTSD Total Symptom Severity Score
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Stress Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00896038 (17) [back to overview]	Alcohol Craving in Response to the Alcohol Cue Script
NCT00945321 (2) [back to overview]	Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg
NCT00945321 (2) [back to overview]	Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.
NCT00952341 (8) [back to overview]	Time to First Vomiting Episode in Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With Complete Response in the Acute Phase of Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With No Impact on Daily Life in Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1
NCT00952341 (8) [back to overview]	Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1
NCT00954941 (2) [back to overview]	Treatment Success Rate
NCT00954941 (2) [back to overview]	Participant Responses
NCT00990821 (1) [back to overview]	Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V
NCT00999544 (2) [back to overview]	Respiration Depression
NCT00999544 (2) [back to overview]	Abuse Liability Proxy
NCT01012336 (1) [back to overview]	Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation of Chemotherapy.
NCT01031953 (8) [back to overview]	Participants With Specific Side Effects, Including Pain Sensation/Soreness at the Infusion Site, Headache, and Dizziness
NCT01031953 (8) [back to overview]	Improvement in Nausea Score From 2 Hours to 24 Hours
NCT01031953 (8) [back to overview]	Improvement in Nausea Score From Baseline to 2 Hours as Assessed by the Numerical Visual Analogue Scale
NCT01031953 (8) [back to overview]	Number of Participants Who Experienced Vomiting Episodes From Baseline to 24 Hours
NCT01031953 (8) [back to overview]	Participants Achieving a Complete Response (no Emesis, no Additional Rescue Medication Required)
NCT01031953 (8) [back to overview]	Improvement in Nausea Score From Baseline to 12 Hours
NCT01031953 (8) [back to overview]	Participants Who Required the Use of Second Rescue Drug (Time to Treatment Failure)
NCT01031953 (8) [back to overview]	Participants With Increased Fatigue or Sedation Within 24 Hours After Receiving Fosaprepitant
NCT01074255 (1) [back to overview]	Investigator Global Assessment of Participants' Response to Therapy With EMEND (Aprepitant) for the Prevention of Acute and Delayed Nausea Following Chemotherapy
NCT01111851 (4) [back to overview]	Brain NK1-receptor Occupancy at 120 Hours Post Dose
NCT01111851 (4) [back to overview]	Brain NK1-receptor Occupancy at 48 Hours Post Dose
NCT01111851 (4) [back to overview]	Brain NK1-receptor Occupancy at 24 Hours Post Dose
NCT01111851 (4) [back to overview]	Brain NK1-receptor Occupancy at the Time of the Maximum Concentration (Tmax)
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Heartburn During the Day Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Heartburn When Lying Down Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Loss of Appetite Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Lower Abdominal Discomfort Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Lower Abdominal Pain Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Nausea Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Nausea/Vomiting Severity Subscore
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Regurgitation During the Day Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Regurgitation When Lying Down Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Retching Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Stomach Distention Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Stomach Fullness Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Unable to Finish Meal Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Upper Abdominal Discomfort Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Upper Abdominal Pain Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Upper Abdominal Pain Subscore
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Vomiting Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity: Bitter Taste Severity
NCT01149369 (80) [back to overview]	Platelet Count
NCT01149369 (80) [back to overview]	Potassium
NCT01149369 (80) [back to overview]	Red Blood Cell Count (RBC)
NCT01149369 (80) [back to overview]	Satiety Test, Volume Consumed
NCT01149369 (80) [back to overview]	Sodium
NCT01149369 (80) [back to overview]	State-Trait Anxiety Inventory (STAI): State Anxiety Score
NCT01149369 (80) [back to overview]	State-Trait Anxiety Inventory (STAI): Trait Anxiety Score
NCT01149369 (80) [back to overview]	White Blood Cell Count (WBC)
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Upper Abdominal Pain Severity
NCT01149369 (80) [back to overview]	Beck Depression Inventory (BDI) Score
NCT01149369 (80) [back to overview]	Blood Urea Nitrogen (BUN)
NCT01149369 (80) [back to overview]	Brief Pain Inventory: Interference Score
NCT01149369 (80) [back to overview]	Brief Pain Inventory: Severity Score
NCT01149369 (80) [back to overview]	Calcium
NCT01149369 (80) [back to overview]	Carbon Dioxide
NCT01149369 (80) [back to overview]	Chloride
NCT01149369 (80) [back to overview]	Clinical Global Patient Impression Score (Patient-rated)
NCT01149369 (80) [back to overview]	Creatinine
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Bradygastria (1-<2.5 Cpm) at 4 Weeks, 0-30 Post-satiety Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Bradygastria (1-<2.5 Cpm) at 4 Weeks, Baseline Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Duodenal (>10-15 Cpm) at 4 Weeks, 0-30 Post-satiety Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Duodenal (>10-15 Cpm) at 4 Weeks, Baseline Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Normogastria (2.5-<3.8 Cpm) at 4 Weeks, 0-30 Post-satiety Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Normogastria (2.5-<3.8 Cpm) at 4 Weeks, Baseline Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Tachygastria (3.8-10 Cpm) at 4 Weeks, 0-30 Post-satiety Measurement
NCT01149369 (80) [back to overview]	Electrogastrography (EGG): Tachygastria (3.8-10 Cpm) at 4 Weeks, Baseline Measurement
NCT01149369 (80) [back to overview]	Gastrointestinal Symptom Rating Scale (GSRS): Abdominal Pain Score
NCT01149369 (80) [back to overview]	Gastrointestinal Symptom Rating Scale (GSRS): Constipation Score
NCT01149369 (80) [back to overview]	Gastrointestinal Symptom Rating Scale (GSRS): Diarrhea Score
NCT01149369 (80) [back to overview]	Gastrointestinal Symptom Rating Scale (GSRS): Indigestion Score
NCT01149369 (80) [back to overview]	Gastrointestinal Symptom Rating Scale (GSRS): Reflux Score
NCT01149369 (80) [back to overview]	Gastrointestinal Symptom Rating Scale (GSRS): Total Score
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Bloating Severity
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Early Satiety Severity
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Excessive Fullness Severity
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): GCSI Total Score
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Nausea (Hours)
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Nausea Severity
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Overall Symptom Severity
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Retching (No. Episodes)
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Vomiting (No. Episodes)
NCT01149369 (80) [back to overview]	Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD): Vomiting Severity
NCT01149369 (80) [back to overview]	Glucose
NCT01149369 (80) [back to overview]	Hematocrit
NCT01149369 (80) [back to overview]	Hemoglobin
NCT01149369 (80) [back to overview]	Hemoglobin A1c (HbA1c)
NCT01149369 (80) [back to overview]	Liver Enzymes and Proteins: Alanine Aminotransferase (ALT)
NCT01149369 (80) [back to overview]	Liver Enzymes and Proteins: Albumin
NCT01149369 (80) [back to overview]	Liver Enzymes and Proteins: Aspartate Aminotransferase (AST)
NCT01149369 (80) [back to overview]	Liver Enzymes and Proteins: Total Protein
NCT01149369 (80) [back to overview]	Magnesium
NCT01149369 (80) [back to overview]	Number of Participants With Improvement in Nausea
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Bloating Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Bloating Subscore
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Chest Discomfort During Sleep Time Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Chest Discomfort During the Day Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Constipation Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Diarrhea Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Excessive Fullness Severity
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Fullness/Early Satiety Subscore
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: Gastroparesis Cardinal Symptom Index (GCSI) Score
NCT01149369 (80) [back to overview]	PAGI-SYM Severity Index: GERD Subscore
NCT01176591 (6) [back to overview]	Alcohol Craving as Measured by the Visual Analog Scale (VAS) 1
NCT01176591 (6) [back to overview]	Alcohol Craving as Measured by the Visual Analog Scale (VAS) 2
NCT01176591 (6) [back to overview]	Cocaine Craving as Measured on the Visual Analog Scale (VAS) 1
NCT01176591 (6) [back to overview]	Cocaine Craving as Measured on the Visual Analog Scale (VAS) 2
NCT01176591 (6) [back to overview]	Multiple Choice Procedure (MCP) 1
NCT01176591 (6) [back to overview]	Multiple Choice Procedure (MCP) 2
NCT01183481 (5) [back to overview]	Control Rate of Delayed Phase Nausea, Vomiting, and Retching in Patients Undergoing Multiple Fraction Radiotherapy
NCT01183481 (5) [back to overview]	Control Rate of Delayed Phase Nausea, Vomiting, and Retching in Patients Undergoing Single Fraction Radiotherapy
NCT01183481 (5) [back to overview]	Control Rate of Acute Phase Nausea, Vomiting, and Retching in Patients Undergoing Single Fraction Radiotherapy
NCT01183481 (5) [back to overview]	Control Rate of Acute Phase Nausea, Vomiting, and Retching in Patients Undergoing Multiple Fraction Radiotherapy
NCT01183481 (5) [back to overview]	The Proportion of Patients Experiencing no Vomiting and no Nausea, Without Use of Any Rescue Antiemetic Medication(s), From Days 2-10 Following the Radiation Therapy (Delayed RINV).
NCT01275664 (2) [back to overview]	Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0
NCT01275664 (2) [back to overview]	Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)
NCT01298193 (9) [back to overview]	Number of Participants With Complete Response (CR) in Cycle 2 for Patient Without Complete Response in Cycle 1
NCT01298193 (9) [back to overview]	Total Impact of Chemotherapy-Induced Nausea and Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2
NCT01298193 (9) [back to overview]	Total Impact of Chemotherapy-Induced Nausea and Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Vomiting on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Nausea on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 2
NCT01298193 (9) [back to overview]	Impact of Chemotherapy-Induced Nausea on Daily Life by the Functional Living Index-Emesis Questionnaire in Cycle 1
NCT01298193 (9) [back to overview]	Number of Participants With Treatment Related Adverse Events (AE) at Cycle 2
NCT01298193 (9) [back to overview]	Number of Participants With Complete Response (CR)
NCT01334086 (5) [back to overview]	Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5
NCT01334086 (5) [back to overview]	Percentage of Patients' Use of Supplemental Anti-emetics as Determined by the Total Number of Doses Per Day and in Total, From Days 1-8.
NCT01334086 (5) [back to overview]	Daily Number of Vomiting or Retching Incidents From Days 1-8
NCT01334086 (5) [back to overview]	Percentage of Patients Experiencing Nausea From Days 1-8.
NCT01334086 (5) [back to overview]	Percentage of Participants Experiencing Vomiting or Retching From Days 1-8.
NCT01362530 (4) [back to overview]	Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1
NCT01362530 (4) [back to overview]	Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1
NCT01362530 (4) [back to overview]	Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1
NCT01362530 (4) [back to overview]	Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1
NCT01376297 (1) [back to overview]	Percentage of Patients With Adverse Events
NCT01405924 (6) [back to overview]	Percentage of Participants With No Vomiting and No Retching During Cycle 2 of Chemotherapy
NCT01405924 (6) [back to overview]	Percentage of Participants With No Significant Nausea During Cycle 2 of Chemotherapy
NCT01405924 (6) [back to overview]	Percentage of Participants With a Complete Response During Cycle 2 of Chemotherapy
NCT01405924 (6) [back to overview]	Percentage of Participants Who Used No Rescue Medication During Cycle 2 of Chemotherapy
NCT01405924 (6) [back to overview]	Percentage of Participants With No Vomiting and No Retching During Cycle 2 of Chemotherapy Per Type of Chemotherapy
NCT01405924 (6) [back to overview]	Functional Living Index - Emesis (FLIE) Total Score During Cycle 2 of Chemotherapy
NCT01432015 (2) [back to overview]	Overall Complete Response Rate
NCT01432015 (2) [back to overview]	Impact on Daily Living Activities
NCT01450826 (4) [back to overview]	Patient's Global Satisfaction With the Antiemetic Regimen
NCT01450826 (4) [back to overview]	Proportion of Patients Achieving Complete Control (CC)
NCT01450826 (4) [back to overview]	Time to Treatment Failure
NCT01450826 (4) [back to overview]	Proportion of Patients Achieving an Acute and Delayed Complete Response (CR)
NCT01474915 (2) [back to overview]	Post Operative Nausea and Vomiting (PONV) Scores on a Verbal Response Scale
NCT01474915 (2) [back to overview]	Proportion of Patients With a Complete Response/Complete Control During the First 24 Hours After Neurological Surgery Under General Anesthesia
NCT01490060 (1) [back to overview]	Complete Response
NCT01504711 (4) [back to overview]	Overall Survival
NCT01504711 (4) [back to overview]	Percentage of Participants With Control of Vomiting and Rescue Medication Control
NCT01504711 (4) [back to overview]	Percentage of Participants With Control of Both Acute and Delayed Vomiting
NCT01504711 (4) [back to overview]	Percentage of Participants With Control of Both Acute and Delayed Nausea
NCT01534637 (3) [back to overview]	Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based Chemotherapy With Upper Abdominal Radiation
NCT01534637 (3) [back to overview]	Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Taking Anti Nausea Drugs
NCT01534637 (3) [back to overview]	Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Using Anti Nausea Drugs
NCT01580423 (3) [back to overview]	Intensity of Breathlessness
NCT01580423 (3) [back to overview]	Intensity of Pain
NCT01580423 (3) [back to overview]	Unpleasantness of Breathlessness
NCT01594749 (6) [back to overview]	Percentage of Participants With Severe Infusion-site Reactions
NCT01594749 (6) [back to overview]	Percentage of Participants With Complete Response From 0 to 120 Hours After Initiation of MEC
NCT01594749 (6) [back to overview]	Percentage of Participants With No Vomiting From 0 to 120 Hours After Initiation of MEC
NCT01594749 (6) [back to overview]	Percentage of Participants With Infusion-site Thrombophlebitis
NCT01594749 (6) [back to overview]	Percentage of Participants With Complete Response From 0 to 24 Hours After Initiation of MEC
NCT01594749 (6) [back to overview]	Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC)
NCT01611948 (1) [back to overview]	Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8
NCT01625455 (2) [back to overview]	Quality of Life
NCT01625455 (2) [back to overview]	Severity of Pruritus
NCT01636947 (8) [back to overview]	Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]	Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]	Percentage of Participants With No Vomiting - Acute and Delayed Stages
NCT01636947 (8) [back to overview]	Number of Emetic Events - Overall Stage
NCT01636947 (8) [back to overview]	Percentage of Participants With No Impact on Daily Life - Overall Stage
NCT01636947 (8) [back to overview]	Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage
NCT01636947 (8) [back to overview]	Percentage of Participants With One or More Clinical Adverse Event
NCT01636947 (8) [back to overview]	The Percentage of Participants With No Vomiting - Overall Stage
NCT01640340 (6) [back to overview]	Delayed CR (Complete Response)
NCT01640340 (6) [back to overview]	Use of Rescue Medication for Each Treatment Arm
NCT01640340 (6) [back to overview]	Acute CR (Complete Response)
NCT01640340 (6) [back to overview]	Overall CR(Complete Response)After the First Course of HEC, Defined as no Emesis and no Use of Rescue Medication
NCT01640340 (6) [back to overview]	Percentage of Patients Who Experienced Grade 1, 2 or 3 Nausea From Time 0 to 120 Hours
NCT01640340 (6) [back to overview]	Percentage of Patients Who Experienced Grade 1, 2 or 3 Vomiting From Time 0 to 120 Hours
NCT01697579 (33) [back to overview]	Area Under the Concentration-time Curve of Aprepitant From Time 0 to Infinity (AUC 0-∞) in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	Area Under the Concentration-time Curve of Aprepitant From Time 0 to 24 Hours (AUC 0-24hr) in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	Apparent Total Body Clearance (CL/F) of Aprepitant in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	Apparent Terminal Half-life (t1/2) of Aprepitant in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	C24hr of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	AUC 0-24hr of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	C24hr of Aprepitant in Participants 12 to 17 Years of Age
NCT01697579 (33) [back to overview]	Cmax of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	C48hr of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	Cmax of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	Concentration of Aprepitant After 24 Hours (C24hr) in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	Concentration of Aprepitant After 48 Hours (C48hr) in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	CL/F of Aprepitant in Participants 12 to 17 Years of Age
NCT01697579 (33) [back to overview]	Maximum Concentration (Cmax) of Aprepitant in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event (AE) in Cycle 1
NCT01697579 (33) [back to overview]	Percentage of Participants Who Experienced at Least One Adverse Event (AE) in Cycles 2-6
NCT01697579 (33) [back to overview]	t1/2 of Aprepitant in Participants 12 to 17 Years of Age Hours
NCT01697579 (33) [back to overview]	t1/2 of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	C24hr of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	AUC 0-24hr of Aprepitant in Participants 12 to 17 Years of Age
NCT01697579 (33) [back to overview]	AUC 0-∞ of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	AUC 0-∞ of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	t1/2 of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	Time to Maximum Concentration (Tmax) of Aprepitant in Participants 0 to <2 Years of Age
NCT01697579 (33) [back to overview]	Tmax of Aprepitant in Participants 12 to 17 Years of Age
NCT01697579 (33) [back to overview]	C48hr of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	Tmax of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	AUC 0-∞ of Aprepitant in Participants 12 to 17 Years of Age
NCT01697579 (33) [back to overview]	AUC 0-24hr of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	CL/F of Aprepitant in Participants 2 to <6 Years of Age
NCT01697579 (33) [back to overview]	CL/F of Aprepitant in Participants 6 to <12 Years of Age
NCT01697579 (33) [back to overview]	Cmax of Aprepitant in Participants 12 to 17 Years of Age
NCT01697579 (33) [back to overview]	Tmax of Aprepitant in Participants 2 to <6 Years of Age
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 125 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 40 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 40 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 40 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Maximum Concentration (Cmax) of Aprepitant Following Administration of 125 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	Percentage of Participants Discontinuing Study Due to an AE
NCT01732458 (38) [back to overview]	Time to Maximum Concentration (Tmax) of Aprepitant Following Administration of 125 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	Tmax Following Administration of 40 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 125 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 125 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 125 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 40 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 40 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 40 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Percentage of Participants Experiencing at Least One Adverse Event (AE)
NCT01732458 (38) [back to overview]	Tmax of Aprepitant Following Administration of 10 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Area Under the Concentration-time Curve of Aprepitant From Time 0 to the Last Measurable Concentration (AUC0-last) Following Administration of 125 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last Following Administration of 10 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last Following Administration of 40 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 10 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 10 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 10 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 125 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 125 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 125 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 40 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 40 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	AUC0-last of Aprepitant Following Administration of 40 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Cmax Following Administration of 40 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 12 to 17 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 10 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 10 mg Dose Equivalent in Birth to <2 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 125 mg Dose Equivalent in 2 to <6 Year Age Group
NCT01732458 (38) [back to overview]	Cmax of Aprepitant Following Administration of 125 mg Dose Equivalent in 6 to <12 Year Age Group
NCT01736917 (4) [back to overview]	Self-Reported Assessment of Nausea
NCT01736917 (4) [back to overview]	Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting
NCT01736917 (4) [back to overview]	Use of Rescue Medications.
NCT01736917 (4) [back to overview]	Total Number of Emetic Episodes
NCT01854177 (2) [back to overview]	Intensity of Breathlessness
NCT01854177 (2) [back to overview]	Unpleasantness of Breathlessness
NCT01857232 (2) [back to overview]	Number of Participants With CR in the Overall Phase.
NCT01857232 (2) [back to overview]	Number of Participants With Delayed Phase Complete Response(CR)
NCT01874119 (1) [back to overview]	Number of Patients With Complete Response During Inpatient Admission
NCT01963793 (16) [back to overview]	Clinical Score Assessment of Infiltration
NCT01963793 (16) [back to overview]	Lesional Erythema by Mexameter
NCT01963793 (16) [back to overview]	Daily Assessments of Duration of Pruritus (Preceding 12 Hours)
NCT01963793 (16) [back to overview]	Pruritus by VAS (Visual Analogue Scale)
NCT01963793 (16) [back to overview]	Non-lesional Melanin by Mexameter
NCT01963793 (16) [back to overview]	Daily Assessments of Maximum Intensity of Pruritus by Use of a VAS
NCT01963793 (16) [back to overview]	Clinical Score Assessment of Crusting
NCT01963793 (16) [back to overview]	Melanin by Mexameter
NCT01963793 (16) [back to overview]	Non-lesional Erythema by Mexameter
NCT01963793 (16) [back to overview]	Percent Change From Baseline in Pruritis Assessed by VAS at End of Treatment
NCT01963793 (16) [back to overview]	Pruritus by VAS (Visual Analogue Scale)
NCT01963793 (16) [back to overview]	Change From Baseline in Participants' Global Assessment on Treatment Areas
NCT01963793 (16) [back to overview]	Transepidermal Water Loss (TEWL)
NCT01963793 (16) [back to overview]	Clinical Score Assessment of Erythema
NCT01963793 (16) [back to overview]	Clinical Score Assessment of Scratch Artefacts
NCT01963793 (16) [back to overview]	Daily Assessments of Average Pruritus by Use of a VAS
NCT02097823 (6) [back to overview]	Number of Participants With Adverse Events.
NCT02097823 (6) [back to overview]	Feasibility of Recruitment and Data Collection.
NCT02097823 (6) [back to overview]	Complete Response in Overall Phase
NCT02097823 (6) [back to overview]	Complete Response in Delayed Phase
NCT02097823 (6) [back to overview]	Good Control of Nausea
NCT02097823 (6) [back to overview]	Complete Response in Acute Phase
NCT02106494 (5) [back to overview]	Delayed Complete Control (CC) Rate
NCT02106494 (5) [back to overview]	Delayed Phase Complete Response (CR) Rate
NCT02106494 (5) [back to overview]	Overall Complete Control Rate
NCT02106494 (5) [back to overview]	Rate of No Emetic Episodes
NCT02106494 (5) [back to overview]	Overall Complete Response Rate
NCT02116530 (5) [back to overview]	Frequency of Rescue Medication
NCT02116530 (5) [back to overview]	Proportion of Patients With Complete Response
NCT02116530 (5) [back to overview]	Proportion of Patients With no Nausea
NCT02116530 (5) [back to overview]	Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT02116530 (5) [back to overview]	Median Nausea Scores
NCT02130687 (12) [back to overview]	Norepinephrine (NE) Concentrations
NCT02130687 (12) [back to overview]	Neuropeptide Y
NCT02130687 (12) [back to overview]	Mean Arterial Blood Pressure
NCT02130687 (12) [back to overview]	Dipeptidyl Peptidase IV (DPP4) Activity
NCT02130687 (12) [back to overview]	Glucose
NCT02130687 (12) [back to overview]	Heart Rate
NCT02130687 (12) [back to overview]	Heart Rate
NCT02130687 (12) [back to overview]	Low Frequency Variability of Blood Pressure Activity
NCT02130687 (12) [back to overview]	24hr Urinary Testing for Sodium
NCT02130687 (12) [back to overview]	Mean Arterial Blood Pressure
NCT02130687 (12) [back to overview]	Insulin
NCT02130687 (12) [back to overview]	Angiotensin Converting Enzyme (ACE) Activity
NCT02210195 (2) [back to overview]	Change From Week 0 in Drinking Quantity and Frequency Using Drinks Per Week at Week 8
NCT02210195 (2) [back to overview]	Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving MEC With No Vomiting in the Overall Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving HEC With Complete Response in Overall Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving HEC With Complete Response in the Acute Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving HEC With Complete Response in the Delayed Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving HEC With No Vomiting in the Acute Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving HEC With No Vomiting in the Delayed Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving HEC With No Vomiting in the Overall Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving MEC With Complete Response in Overall Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving MEC With Complete Response in the Acute Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving MEC With Complete Response in the Delayed Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving MEC With No Vomiting in the Acute Phase
NCT02484911 (12) [back to overview]	Proportion of Participants Receiving MEC With No Vomiting in the Delayed Phase
NCT02519842 (6) [back to overview]	Percentage of Participants Who Experienced a Complete Response During the Acute Phase (0 to 24 Hours Post Initiation of Chemotherapy) in Cycle 1
NCT02519842 (6) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT02519842 (6) [back to overview]	Percentage of Participants Who Experienced a Complete Response During the Delayed Phase (>24 to 120 Hours Post Initiation of Chemotherapy) in Cycle 1
NCT02519842 (6) [back to overview]	Percentage of Participants Who Experienced a Complete Response During the Overall Phase (0 to 120 Hours Post Initiation of Chemotherapy) in Cycle 1
NCT02519842 (6) [back to overview]	Percentage of Participants Who Experienced One or More Adverse Events
NCT02519842 (6) [back to overview]	Percentage of Participants Who Experienced No Vomiting, Regardless of Rescue Medication Use, During the Overall Phase (0 to 120 Hours Post Initiation of Chemotherapy) in Cycle 1
NCT02597907 (1) [back to overview]	The Incidence of Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]	PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]	Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]	Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02625181 (4) [back to overview]	The Number of Prophylactic Interventions for PONV
NCT02732015 (1) [back to overview]	Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose
NCT02780609 (5) [back to overview]	Phase I: Recommended Phase II Dose (RPh2D)
NCT02780609 (5) [back to overview]	Rate of Minimal Residual Disease (MRD)
NCT02780609 (5) [back to overview]	Phase 1 and Phase 2 Percentage of Participants Treated at Dose Level 3/RP2D With Progression Free Survival (PFS)
NCT02780609 (5) [back to overview]	Overall Survival (OS)
NCT02780609 (5) [back to overview]	Complete Response (CR)
NCT03197064 (5) [back to overview]	Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Upper Extremity)
NCT03197064 (5) [back to overview]	Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Right Lower Extremity)
NCT03197064 (5) [back to overview]	Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Upper Extremity)
NCT03197064 (5) [back to overview]	Somatosensory Evoked Potentials (SEPs), Extremity Amplitude (Left Lower Extremity)
NCT03197064 (5) [back to overview]	Motor Evoked Potentials Amplitude (Left Upper Extremity)
NCT03237611 (4) [back to overview]	Complete Control Rate of Chemotherapy-induced Nausea and Vomiting (CINV) Following 2nd Cycle of Chemotherapy
NCT03237611 (4) [back to overview]	Complete Control Rate of Chemotherapy-induced Nausea and Vomiting (CINV) Following 1st Cycle of Chemotherapy
NCT03237611 (4) [back to overview]	Complete Control Rate of Chemotherapy-induced Nausea and Vomiting (CINV) Following 1st Cycle of Chemotherapy
NCT03237611 (4) [back to overview]	Complete Control Rate of Chemotherapy-induced Nausea and Vomiting (CINV) Following 2nd Cycle of Chemotherapy
NCT03578081 (5) [back to overview]	Complete Response (CR) (no Emetic Episodes and no Use of Rescue Medication) During the Acute, Delayed and the Overall Periods as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]	Potential Toxicities as Ascribed to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]	Total Frequency of Rescue Medication as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]	Average Nausea Scores (0-10) Repeatedly Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT03578081 (5) [back to overview]	No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and Delayed (24-120 Hours) Periods
NCT03718039 (5) [back to overview]	Mean Area Under the Curve (AUC) of the NRS-R (Windowed Worst Observation Carried Forward) Pain Intensity Scores
NCT03718039 (5) [back to overview]	Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) Through 72 Hours
NCT03718039 (5) [back to overview]	Percentage of Subjects Receiving no Opioid Rescue
NCT03718039 (5) [back to overview]	Mean Area Under the Curve (AUC) of the NRS-A (Windowed Worst Observation Carried Forward) Pain Intensity Scores
NCT03718039 (5) [back to overview]	Percentage of Subjects Receiving no Opioid Rescue
NCT04054193 (2) [back to overview]	Percentage of Participants in Cycle 1 Who Discontinued Study Drug Due to an Adverse Event (AE)
NCT04054193 (2) [back to overview]	Percentage of Participants in Cycle 1 Who Experienced One or More Adverse Events (AEs)
NCT04470622 (5) [back to overview]	Time to Discharge From Hospital.
NCT04470622 (5) [back to overview]	Incidence of Treatment-emergent Adverse Events.
NCT04470622 (5) [back to overview]	Time to Death or Respiratory Failure, Defined as Any of the Following: Endotracheal Intubation and Mechanical Ventilation; Oxygen Delivered by High-flow Nasal Cannula; Noninvasive Positive Pressure Ventilation; Extracorporeal Membrane Oxygenation (ECMO).
NCT04470622 (5) [back to overview]	Proportion of Subjects Alive and Discharged From the Hospital.
NCT04470622 (5) [back to overview]	Change From Baseline in Interleukin 6 (IL-6).

Number of Patients With Clinical Adverse Experiences (CAEs)

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product (NCT00231777)
Timeframe: Baseline and 24 hours

Intervention	Participants (Number)
MK0517 Intravenous (IV) 40 mg	125
Ondansetron IV 4 mg	32

Intervention	Participants (Count of Participants)
	CC	CR	MR	Failure	NSN
Group A - Subjects With Multiple Myeloma	0	0	8	1	0	6
Group B - Subjects With Relpased Lymphoma	1	0	6	2	0	5

Intervention	participants (Number)
Aprepitant and Placebo Transdermal Patch	28
Aprepitant and Scopolamine Transdermal Patch	34

Intervention	participants (Number)
Group A(Oral Aprepitant+iv Ondansetron)	7
Group B(Oral Placebo+iv Ondansetron)	22

Intervention	participants (Number)
Aprepitant and Scopolamine Group	24
Aprepitant and Placebo Scopolamine Group	29

Intervention	participants (Number)
Aprepitant and Scopolamine Group	5
Aprepitant and Scopolamine Placebo Group	2

Intervention	units on a scale (Mean)
	0-2 hours post op	24 hours post op	48 hours post op
Aprepitant	0.4	0.8	0.9
Ondansetron	0.6	1.3	1.1

Intervention	participants (Number)
Arm 1-medication Pre and Post Procedure	6
Arm 2-Randomized to Placebo	9

Intervention	Participants (Number)
Part IA-fosaprepitant 115 mg/Aprepitant	0
Part IB-fosaprepitant 150 mg	0
Part IIA-aprepitant 80 mg Equiv.	0
Part IIB-aprepitant 125 mg Equiv.	0
Part III-ondansetron	0
Part IV-aprepitant Regimen	0
Part V-fosaprepitant Regimen	1

Intervention	hr (Mean)
	6 months to <2 years (n=0, 0, 5, 3, 0, 3, 6)	2 years to <6 years (n=0, 0, 6, 4, 0, 5, 7)	6 years to <12 years (n=0, 0, 5, 6, 0, 4, 8)	12 years to 17 years (n=6 11, 0, 0, 0, 0, 0)
Part IA-fosaprepitant 115 mg/Aprepitant	NA	NA	NA	11.0
Part IB-fosaprepitant 150 mg	NA	NA	NA	22.2
Part IIA-aprepitant 80 mg Equiv.	7.28	8.27	9.17	NA
Part IIB-aprepitant 125 mg Equiv.	8.09	6.06	6.89	NA
Part IV-aprepitant Regimen	6.18	9.21	10.8	NA
Part V-fosaprepitant Regimen	7.71	6.44	8.76	NA

Intervention	hr*ng/mL (Mean)
	6 months to <2 years (n=0, 0, 5, 5, 0, 6, 6)	2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7)	6 years to <12 years (n=0, 0, 6, 6, 0, 6, 8)	12 years to 17 years (n=8, 11, 0, 0, 0, 0, 0)
Part IA-fosaprepitant 115 mg/Aprepitant	NA	NA	NA	19500
Part IB-fosaprepitant 150 mg	NA	NA	NA	30800
Part IIA-aprepitant 80 mg Equiv.	20000	16400	16000	NA
Part IIB-aprepitant 125 mg Equiv.	6310	23000	22000	NA
Part IV-aprepitant Regimen	21100	17300	24400	NA
Part V-fosaprepitant Regimen	11700	18300	19500	NA

Intervention	hr (Mean)
	6 months to <2 years (n=0, 0, 0, 0, 0, 0, 7)	2 years to <6 years (n=0, 0, 0, 0, 0, 0, 7)	6 years to <12 years (n=0, 0, 0, 0, 0, 0, 8)	12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0)
Part IB-fosaprepitant 150 mg	NA	NA	NA	0.614
Part V-fosaprepitant Regimen	1.13	1.05	1.04	NA

Intervention	ng/mL (Mean)
	6 months to <2 years (n=0, 0, 5, 5, 0, 6, 7)	2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7)	6 years to <12 years (n=0, 0, 6, 6, 0, 7, 8)	12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0)
Part IA-fosaprepitant 115 mg/Aprepitant	NA	NA	NA	3240
Part IB-fosaprepitant 150 mg	NA	NA	NA	5870
Part IIA-aprepitant 80 mg Equiv.	1930	1300	1300	NA
Part IIB-aprepitant 125 mg Equiv.	659	2100	1930	NA
Part IV-aprepitant Regimen	1810	1840	1800	NA
Part V-fosaprepitant Regimen	1700	2430	2850	NA

Intervention	Participants (Number)
Part 1: Oral Aprepitant	0
Part 2: Oral Aprepitant	0
Part 2: Intravenous Ondansetron	0

Intervention	hr*ug/ml (Mean)
	6 months to <2 years (n=11)	2 years to <6 years (n=11)	6 years to <12 years (n=11)	12 years to 17 years (n=10)
Part 1: Oral Aprepitant	5.97	4.76	6.16	6.01

Intervention	Participants (Number)
	No Vomiting	1 Vomiting Episode	2 Vomiting Episodes	3 Vomiting Episodes	>3 Vomiting Episodes
Part 2: Intravenous Ondansetron	20	3	1	0	1
Part 2: Oral Aprepitant	20	5	0	0	0

Intervention	ng•hr/mL (Mean)
165 mg Aprepitant (Fasted State)	34589
185 mg Aprepitant (Fasted State)	39053
150 mg Fosaprepitant Dimeglumine (Fasted State)	37375
165 mg Aprepitant (Light)	37795
165 mg Aprepitant (High-Fat)	50172
185 mg Aprepitant (Light)	51146
185 mg Aprepitant (High-Fat)	60578

Intervention	ng/mL (Mean)
165 mg Aprepitant (Fasted State)	1738
185 mg Aprepitant (Fasted State)	1636
165 mg Aprepitant (Light)	1870
165 mg Aprepitant (High-Fat)	2362
185 mg Aprepitant (Light)	2116
185 mg Aprepitant (High-Fat)	1995

Intervention	participants (Number)
	Complete Response	Partial Response	No Response
Group 1: Ondansetron	20	9	13
Group 2: Ondansetron + Aprepitant	21	12	8

Intervention	ng*hr/mL (Least Squares Mean)
Aprepitant (125 mg)	29215
MK-0517 (100 mg)	24961
MK-0517 (115 mg)	31724

Intervention	number of breaths per minute (Mean)
Placebo Aprepitant/0 mg Oxycodone IN PO	13.75
Placebo Aprepitant/ Oxycodone 15 IN 0 PO	11.63
Placebo Aprepitant/ Oxycodone 30 IN 0 PO	11.25
Placebo Aprepitant/ Oxycodone 0 IN 20 PO	12.13
Placebo Aprepitant/ Oxycodone 0 IN 40 PO	10.25
Aprepitant 40 mg/ Oxycodone 0 IN 0 PO	12.25
Aprepitant 40 mg/ Oxycodone 0 IN 20 PO	12.25
Aprepitant 40 mg/ Oxycodone 0 IN 40 PO	11.00
Aprepitant 40 mg/ Oxycodone 15 IN 0 PO	12.38
Aprepitant 40 mg/ Oxycodone 30 IN 0 PO	11.63
Aprepitant 200 mg/ Oxycodone 0 IN 0 PO	14.00
Aprepitant 200 mg/ Oxycodone 0 IN 20 PO	14.00
Aprepitant 200 mg/ Oxycodone 0 IN 40 PO	12.13
Aprepitant 200 mg/ Oxycodone 15 IN 0 PO	12.00
Aprepitant 200 mg/ Oxycodone 30 IN 0 PO	11.38

aprepitant

Description

Cross-References

Synonyms (114)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (4)

Protein Targets (48)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (288)

Molecular Functions (101)

Ceullar Components (57)

Bioassays (180)

Research

Studies (737)

Study Types

Clinical Trials (197)

Trial Overview

Trial Outcomes

Number of Patients With Clinical Adverse Experiences (CAEs)

Number of Patients With Drug-related CAEs

Number of Patients With Laboratory Adverse Experiences (LAEs)

Number of Patients With Serious CAEs

Number of Emesis Free Participants During the Study Period.

Overall Nausea Controlled

Delayed Vomiting Controlled

Proportion of Participants With Controlled Acute Vomiting

Toxicity Grade 3, 4, or 5

Number of Patients Who Reported No Vomiting

Number of Patients Who Reported Complete Response

Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.

Home Record: Severity of Delayed Nausea

Proportion of Patients With no Emesis During the Acute CINV Time Period (Cycle Days 1-5)

Preferred Treatment Cycle

Visual Analouge (VAS) 100mm Scale Score

Proportion of Patients With no Emesis During the Delayed CINV Time Period (Cycle Days 6-8)

Complete Response.

MD Anderson Symptom Inventory Score

Overall Emetic Response

Overall Emetic Response: Acute

Overall Emetic Response: Extended

Overall Emetic Response: Delayed

No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)

A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).

A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).

Geometric Mean Area Under Curve (AUC) of Analyte, Vincristine (VC), in Aprepitant Treatment and Control Group

Geometric Mean Area Under Curve (AUC) of Analyte,Prednisone (PR), in Aprepitant Treatment and Control Group

Geometric Mean Area Under Curve (AUC) of Analyte, Prednisolone (PL), in Aprepitant Treatment and Control Group

Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group

Geometric Mean Area Under Curve (AUC) of Analyte, 4-hydroxy-cyclophosphamide (4-OH-CP), in Aprepitant Treatment and Control Group

Geometric Mean Area Under Curve (AUC) of Analyte, 2-dechloro-cyclophosphamide(2-deCI-CP), in Aprepitant Treatment and Control Group

Number of Participants With Postoperative Nausea and Vomiting

Number of Participants Having Post-operative Emesis and Nausea.

Complete Protection

Complete Response (Percentage of Patients)

no Emesis

no Nausea

no Significant Nausea

Number of Participants With Nausea and Vomiting

Number of Participants With Nausea and Vomiting in PACU

Total Vomiting

Need for Antiemetic Medication

Cumulative Incidence of Emesis

Average Nausea Score

Incidence of Vomiting (Post OP)

"Number of Participants Who Rated Their Satisfaction With Antiemetic Management as Very Satisfied"

Number of Vomiting Episodes

Incidence of Vomiting (24 Hours)

Time to First Vomiting

Intervention	units on a scale (points 0-100) (Mean)
Placebo-Placebo (in and po)	0.197
Aprepitant 40 mg - Placebo	0.483
Aprepitant 200 mg- Placebo	0.159
Placebo- 15 mg Oxycodone Intranasal	7.678
Placebo- 30 mg Oxycodone Intranasal	17.450
Placebo- 20 mg Oxycodone Oral	9.850
Placebo - 40 mg Oxycodone Oral	16.646
Aprepitant 40 mg- 15 mg Oxycodone Intranasal	8.543
Aprepitant 40 mg - 30 mg Oxycodone Intranasal	15.092
Aprepitant 40 mg- 20 mg Oxycodone Oral	13.281
Aprepitant 40 mg - 40 mg Oxycodone Oral	17.244
Aprepitant 200 mg - 15 mg Oxycodone Intranasal	17.195
Aprepitant 200 mg - 30 mg Oxycodone Intranasal	28.211
Aprepitant 200 mg- 20 Oxycodone Oral	8.196
Aprepitant 200 mg- 40 Oxycodone Oral	26.322

Intervention	participants (Number)
	Excellent	Good	Fair	Poor	None
Participants Treated With EMEND	438	2056	446	52	3

Intervention	units on a scale (Mean)
Placebo Session 1, Aprepitant Session 2	26.25
Placebo Session 1, Placebo Session 2	38.92

Intervention	units on a scale (Mean)
Placebo Session 1, Aprepitant Session 2	33.22
Placebo Session 1, Placebo Session 2	0.17

Intervention	dollars (Mean)
Placebo Session 1, Aprepitant Session 2	8.58
Placebo Session 1, Placebo Session 2	17.33

Intervention	dollars (Mean)
Placebo Session 1, Aprepitant Session 2	7.59
Placebo Session 1, Placebo Session 2	17.33

Intervention	percentage of participants (Number)
	Control rate of delayed phase nausea	Control rate of delayed phase vomiting/retching
Aprepitant and Granisetron	83	83

Intervention	percentage of participants (Number)
	Control rate of acute phase nausea	Control rate of acute phase vomiting/retching
Aprepitant and Granisetron	100	100

Intervention	Participants (Count of Participants)
	Constipation	Fatigue	Diarrhea	Hyponatremia	Alanine Aminotransferase Increased	GGT Increased
Treatment (Granisetron, Dexamethasone, Aprepitant)	1	1	1	1	1	1

Intervention	score on a scale (Mean)
	Cycle 2 pre-chemotherapy NCR patients	Cycle 2 post-chemotherapy NCR patients	Cycle 2 pre-chemotherapy CR patients	Cycle 2 post-chemotherapy CR patients
Aprepitant NCR	37.8	64.4	43.28	47.7